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Abstract 
Perineural invasion (PNI) is a pathological diagnosis whereby tumour cells infiltrate the 
perineural space of a peripheral nerve. This can lead to perineural spread (PNS) with 
dissemination of tumour cells away from the original tumour mass eventuating in a sensory 
or motor deficit. PNI is an accepted risk factor for poorer prognosis in cutaneous 
squamous cell carcinoma of the head and neck (cSCCHN) with increased locoregional 
recurrence, more aggressive disease and metastasis. Not exclusive to cutaneous 
malignancies, it also portends poorer prognosis in colorectal, cervical, gastric and prostate 
cancers. Despite its prognostic ramifications, PNI and PNS are poorly understood forms of 
tumour metastasis with no prognostic markers nor effective therapies established. 
 
Due to its high significance in cancer signalling, anti-epidermal growth factor receptor 
(EGFR) therapies have emerged to treat epithelial malignancies due to EGFR 
overexpression correlating with increased invasiveness and its potential role in metastasis. 
Combined with the physiological function of EGFR in neural and skin development, EGFR 
represents a therapeutic target in treatment of perineural disease. This thesis aims to 
investigate the metastatic role of promising receptors in the development of PNS from 
cutaneous squamous cell carcinoma (cSCC). Secondly, to establish in vivo and in vitro 
models targeting the function of EGFR and its ligands in PNI and testing anti-EGFR 
combination therapy as a potential therapeutic option. 
 
With analysis of index cSCCHN lesions prior to the development of PNS, EGFR 
overexpression was demonstrated in 70.58% of specimens (24/34) highlighting its 
potential role in perineural disease. HER2 was uniformly negative in index lesions of 
cSCCHN prior to PNS and likely has no role in PNI and PNS of cSCCHN. With the 
importance of the immune system in pathogenesis of cSCC it is not surprising our data 
illustrates a potential role for PD-1/PD-L1 inhibition on cSCCHN with PNI or PNS requiring 
proper elucidation with future work in animal models. Building on previous work from our 
laboratory into in vivo PNS modelling with cSCC, bioluminescent live imaging of tumour 
cells was performed in addition to successful establishment of PNI in 20% (2/10) of mice. 
Finally, development of an in vitro model has potential to further investigate EGFR 
metastatic potential and screen other therapeutic targets. EGFR expression in cSCCHN 
has the potential to prognosticate future perineural disease, with further work required 
through in vivo and in vitro models to investigate treatment options. 
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1 Introduction 
1.1 Background 
Non-melanoma skin cancer (NMSC) encompassing both basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) is the most frequent malignancy worldwide in fair-skinned 
individuals (1). Annually, NMSC develops in an estimated 3 million individuals worldwide 
(2). Australia is the country with the highest rate of NMSC, with approximately 374,000 
people, or near 2% of the total population treated for this condition in 2002 (3). SCC 
contributes significantly to this disease burden approximating 20% of total NMSC cases 
(4). 
 
NMSC is the most costly cancer in Australia with a significant economic burden on the 
healthcare system (5). Over recent decades, the expenditure for treating NMSC by the 
Australian government has significantly increased, costing from $264 million in 2001 to 
nearly double of $511 million in 2010 (5). Despite being a relatively preventable disease, 
over 500 estimated deaths occur from NMSC yearly, accounting for 1.2% of Australian 
total cancer deaths (6).  
 
Cutaneous SCC (cSCC) is a malignant proliferation of squamous epidermal cells with 
prolonged ultraviolet radiation exposure proven as a key determinant (7). Other risk factors 
include sun-sensitive skin, age, immunosuppression and exposure to chemical 
carcinogens. Currently, the estimated incidence of cSCC in Australia is 387 per 100,000 
person-years, and despite the use of sun safety programs, the incidence of SCC continues 
to rise (8).  
 
Perineural invasion (PNI) describes a pathological diagnosis whereby tumour cells infiltrate 
the perineural space of a peripheral nerve (9). When tumour cells disseminate away from 
the original tumour mass within the perineural space, it is defined as perineural spread 
(PNS) and eventuates in a sensory deficit such as dysesthesia or a motor deficit 
depending on the type of somatic nerve involvement (10). Although uncommon, perineural 
invasion (PNI) is an accepted risk factor for poorer prognosis in cSCC of the head and 
neck (cSCCHN) with increased local recurrence, and aggressive disease (11, 12). Not 
exclusive to cutaneous malignancies, it also predicts poor outcomes in mucosal head and 
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neck squamous cell carcinoma (SCCHN), and multiple other malignancies including 
colorectal, cervical, gastric, pancreatic and prostate cancers (13-17).  
 
PNS is an under-recognised form of tumour metastasis despite its prognostic 
ramifications. Additionally, the molecular mechanisms of PNI development are poorly 
understood with no prognostic markers nor effective therapies established (18). Improved 
understanding of PNI pathogenesis would pave the way for the development of targeted 
drug therapies to benefit those afflicted by this aggressive disease.   
 
1.2 Perineural Invasion and Perineural Spread 
1.2.1 Peripheral nerve structure 
An understanding of the peripheral nervous system and nerve structure is imperative to 
comprehend PNI and elucidate its pathogenesis. The human nervous system is partitioned 
into the central nervous system (CNS), constituting the brain and spinal cord, and the 
peripheral nervous system constituting bridging nerves between the CNS and distal 
tissues or organs (19). Of the twelve cranial nerves, all excluding the optic nerve are 
considered peripheral nerves and include the trigeminal and facial nerves that are most 
commonly involved in PNS of cSCCHN (10). These peripheral nerves consist of neurons, 
epithelial cells, fibroblasts and blood vessels, and are subdivided into three layers: the 
epineurium, perineurium and endoneurium (Figure 1.1).  
 
Endoneurium is a loose structure composed of individual axons, partnering Schwann cells, 
fibroblasts, connective tissues and capillaries (20). Assemblies of nerve fibres with their 
encompassing endoneurial layer are bundled into fascicles by a tight perineurial barrier 
(21). This barrier consists of multi-layered flattened epithelial cells, and when coupled with 
condensed collagenous tissue, encircle each fascicle into a concentric sheath (22). A 
potential pathway for cancer invasion emerges underneath the perineurium known as the 
perineural space. Finally, a further layer of elastin and collagen fibres known as the 
epineurium surround clusters of fascicles and blood vessels to form a complete peripheral 
nerve (19). 
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1.2.2 The perineurium 
The perineurium affords physical protection to the peripheral nerve from external insults, 
maintains homeostatic pressures, and functions as a selective diffusion filter (23). This 
blood-nerve barrier consists of tight intercellular junctions or zonulae occludentes between 
perineural epithelial cells and the basement membrane (23) The perineurium blocks the 
passage of carcinogenic, infectious and toxic compounds (23). Initially, endolymphatic 
spread of malignant cells was theorised as a route of PNS (24). However, the perineural 
space has since definitively been shown to be deficient in lymphatic or blood supply (21, 
24, 25).To supply nerve fibres, epineurial blood vessels sheathed in perineural cells 
perforate the perineurium (26). Where peripheral nerves joins with the CNS proximally, the 
epineurium and perineurium continues as the dura mater and pia-arachnoid of the 
meninges respectively (23). Distally, the perineurium thins into a single-layered barrier 
when the peripheral nerve reaches the dermis of the skin, merging with terminal sensory 
endings or motor-end plates (26). Thus, there is a continuous avenue of tumour spread 
between the skin and the brain if the cancer invades the perineural space at any point. 
 
 
 
Figure 1.1 Peripheral nerve anatomy. Illustrates the epineurium, perineural space and 
endoneurium. The perineural layer has combined with the epineurial layer in this distal 
section. Perineural cells (P), axons (A), and supporting Schwann cells (S) are also 
highlighted. Adapted from Brown (2016) (9). 
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Therefore, the two key anatomical locations where perineurium is potentially absent 
include distal nerve endings and traversing epineurial vessels feeding endoneurial nerve 
fibres (23). However a histopathological study by Panizza et al. (2014) investigating PNS 
specimens of cranial nerves from cSCCHN illustrate the effectiveness of the perineurium 
as a barrier to local invasion of tumour (27). Only 2 out of 51 patients had tumour spread 
through the perineurium into the epineurium at the proximal region of cranial nerves, whilst 
epineurial spread was detected in 43% of specimens near the distal peripheral margin 
consistent with a thin-layered or potentially absent perineurium in this region (27). This 
phenomenon was recognised and proposed by Shattock (1922) with Larson et al. (1966) 
and Rodin et al. (1967) theorising central spread following a path of least resistance (24, 
25, 28). However, the nerve sheath with concentrically arranged layers of cells is anything 
but low resistance (18).       
 
1.2.3 Defining Perineural Invasion 
An important attribute of invasive cancer is the ability to spread and metastatically seed 
deposits distant from the primary site. The invasive properties of head and neck cancers 
were described as early as the 1800s with European investigators documenting the 
dissemination of a lower lip tumour along the mental nerve, and highlighting an inclination 
of these cancers for nerve invasion and central spread (29). Despite the early discovery, 
significant progress is still required regarding the investigation of molecular mechanisms 
and pathogenesis of PNI (14, 18). 
 
Subsequently, a multitude of definitions for PNI have been proposed in the literature, 
generating confusion (14, 18, 30, 31). An early established definition was neurotropism, or 
the ability of a tumour to invade peripheral nerves along pathways of least resistance 
including endolymphatic spread (30). The theory of lymphatic metastasis in PNI has since 
been disproven from histologically studies demonstrating an absence of lymphatic vessels 
as discussed previously (21, 25, 30). More recently, Liebig et al. (2009) whilst 
incorporating desirable features of previous definitions, proposed PNI as the presence of 
tumours cells within any three layers of the nerve sheath including tumour that is close or 
contacting the nerve and covering at least a third of the circumference (14, 32). 
Nevertheless, Panizza et al. (2014) were unable to discover evidence of PNI resulting from 
tumour abutting peripheral nerves out of 51 clinical PNI specimens (27). The barrier 
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function of the perineurium raises doubts to the preciseness of including cancer abutting 
nerves as true perineural invasion. There may be innate differences between tumours with 
established invasion of the perineural space against tumours merely abutting or 
circumferentially surrounding a peripheral nerve.  
 
As discussed previously, PNI is theorised to occur where there are anatomical deficits in 
the perineurium, such as in the skin (10). Recent illustrations of PNI demonstrate tumour 
breaking through the perineurium in schematics of pancreatic cancer where the peripheral 
nerves are smaller with a thin perineural barrier.  (Figure 1.2). This is far less likely to 
occur in cSCCHN due the rigorous integrity of this layer as well as lower tumour volumes 
and nerve densities (33). A more likely hypothesis of cSCCHN with PNI  is that tumour 
entry into the perineural space occurs at the nerve periphery in the subcutis of skin where 
an absent or thin perineurium allows the establishment of microscopic PNI and then local 
extension centrally (PNS) (27). The presence of tumour cells may then promote 
neurogenesis, thereby promoting and illustrating the symbiotic nature of PNI (18, 34). 
Other terms in the literature that prognostically differentiates PNI include small and large 
PNI with a cut off of 0.1mm  (33). Nerve size has been shown to be of prognostic 
significance in PNI with nerves sized 0.1mm or greater having increased risk of 
recurrence, metastasis and disease-specific death (35). Incidental PNI has also been used 
to describe small nerve PNI in the absence of clinical symptoms. The definition of PNI 
utilised in this project is as previously proposed, the pathological diagnosis or presence of 
tumour cells within the perineural space, perineurial layers and endoneurium (31).   
 
1.2.4 Defining Perineural Spread and disease progression  
Whilst perineural invasion describes the discovery of cancer in the perineural space of 
peripheral nerves, the process of malignant cell migration along nerves distant from the 
primary tumour describes PNS (36). PNS being synonymous with clinical PNI, defines 
advanced disease with tumour progression into larger, named nerves presenting with 
clinical deficits and/or radiological findings most often months to years after the index 
lesion has been removed (37). The trigeminal nerve and its ophthalmic, maxillary and 
mandibular branches as well as the facial nerve are the most frequently involved in 
cSCCHN with resulting clinical deficit depending on the extent to which these nerves are 
afflicted (38).  
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Patients present with gradual worsening symptoms in the distribution of the nerve 
involved. The common symptoms include numbness, paraesthesia, neuropathic pain and 
formication (tactile sensation generated from crawling insects) if branches of the trigeminal 
nerve are involved and partial or complete facial palsy if the facial nerve is involved (37). 
The median time from onset of symptoms to diagnosis of PNS is 6 months (37).  
Unfortunately, due to the under recognised nature of PNS, the initial symptoms can be 
misdiagnosed as Bell’s palsy (an idiopathic weakness of the facial nerve) or trigeminal 
neuralgia (a chronic pain disorder affecting the trigeminal nerve and its branches). Of 
trigeminal nerve involvement, the maxillary branch was most commonly involved in PNS 
when histopathological specimens were examined, due to the propensity for the primary 
tumours to originate on the sun-exposed mid-face (27).  
 
Tumour cells have the ability to travel retrograde or antegrade, towards or away from the 
brain respectively, with retrograde spread the more common option (27). Antegrade 
invasion is hypothesised to originate secondary to nerve branching points, following nerve 
back toward the periphery as well as proximally (37). Aggressive disease may lead to a 
rare form of tumour dissemination by the cerebrospinal fluid with leptomeningeal 
involvement known as leptomeningeal carcinomatosis (39). Sadly, the natural progression 
of the disease results in death once tumour has accessed the meninges, brainstem or 
brain (36).  
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Figure 1.2 Model of perineural invasion in pancreatic cancer. Structure of a peripheral 
nerve with epineurium, perineurium and endoneurium comprising the triple layer of a 
peripheral nerve sheath. Pancreatic tumour cells are seen to penetrate through all layers, 
including the multi-layered perineurium. This is unlikely the mechanism by which tumour 
cells of cutaneous squamous cell carcinoma of the head and neck gain access to the 
perineural space. Molecular factors implicated in this process include nerve growth factor 
(NGF) and its receptor tropomyosin receptor kinase A (TrkA). Adapted from Bapat et al. 
(2011) (17). 
 
1.3 Diagnosis of perineural disease 
1.3.1 Histopathological features 
PNI is defined as the presence of tumour cells in the layers of the perineurium or beneath, 
and thus a histological diagnosis by pathologists (31). Certain features raise the possibility 
of PNI presence in specimens including large tumour size (>2cm), male gender, mid-face 
location, recurrent tumour and poor differentiation on histology (40, 41). Haematoxylin and 
eosin (H&E) stains of longitudinal and transverse sections are standard in identifying 
tumour invading or near peripheral nerves, with nerve stains such as S100 and epithelial 
cytokeratin stains such as AE1/AE3 helpful in subtle or difficult cases (Figure 1.3). 
Standardised reporting of PNI was only introduced recently in 2014 and care must be 
taken to exclude benign imitators including ganglion cells and endothelial cells associated 
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with intraneural vessels and inflammatory hypertrophy of the perineurium near tumour 
cells (9).  
 
Previous literature has commonly quoted the presence of skip lesions, or regions of PNI 
separated by cancer free tissue suggesting “skips” in tumour growth (27). Cottel (1982) 
described experiences with “skip lesions” post-sectioning from Mohs micrographic surgery, 
or horizontal sequential sectioning followed by histological assessment (42). This 
technique has been shown to be effective with a recent retrospective study of 579 patients, 
illustrating cSCCHN treated with Mohs micrographic surgery to be three times lower risk of 
recurrence over standard excision, adjusting for tumour size and depth of invasion, 
although PNI was not specifically accounted for (43). However, an inherent limitation 
arises in this technique with the transformation of three-dimensional structures into 
uniplanar sections with only partial appreciation of tumour cells (44). Tumour invasion may 
travel asymmetrically along a nerve presenting as “skip” lesions on horizontal sections 
(45). Histological proof of skip lesions has not yet been obtained with a recent 
histopathological study failing to discover skip lesions along PNS specimens (27). Thus 
these “skips” in tumour growth are likely artefactual, secondary to processing of specimens 
(44).  
 
Current standardised pathology reporting of cSCC may ask for nerve size and whether it 
has invaded beyond dermis, but no uniform consensus exists for PNI reporting, likely 
contributed to by the absence of a widely accepted definition (9, 31). Despite this, due to 
mounting evidence of PNI as an important prognostic value, it has been recognised by the 
American Joint Committee on Cancer (AJCC) NMSC staging (10, 11). In the new AJCC 8th 
edition, any presence of PNI will be classified as T3 disease whilst previously classified as 
T1 or T2 depending on presence of other high risk features (46).  
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Figure 1.3 Perineural invasion by squamous cell carcinoma of a peripheral nerve. 
Dual immunohistochemistry staining by S100 and cytokeratin AE1/AE3 illustrating 
squamous cell carcinoma (brown) and nerve (red). Sourced from Berlingeri-Ramos et al. 
(2015) (47). 
 
1.3.2 Radiological features 
Imaging is indispensable in diagnosis of patients presenting with concerning symptoms for 
PNI such as pain, numbness, paraesthesia or weakness of the cranial nerves (48). 
Magnetic resonance imaging (MRI) plays a crucial role in diagnosis, pre-operative 
planning and post-surgical follow-up for recurrence and is the imaging modality of 
preference over computed tomography (CT) due to improved soft tissue delineation (49, 
50). Features that characterise PNI on MRI include enhancement, asymmetrical 
thickening, loss of foraminal fat padding or foraminal erosion (50). Focused or targeted 
MRI towards cranial nerves to generate high-resolution images are required, otherwise 
PNS may be missed. 
 
When describing extent of PNS, a widely adapted zonal classification system initially 
described by Williams et al. (2001) has been utilised that also informs prognostic 
outcomes and stratifies surgical options (Table 1.1). Warren et al. (2016) has illustrated 
zone 3 disease to have significantly worse survival outcomes than zone 1 disease (zone 1, 
2 and 3 with 84%, 63% and 16% disease-specific survival respectively ; p <0.0001) (37). 
Imaging of PNI has been well studied quoting both high sensitivity and specificity when 
MRI neurography (optimised for water properties of nerves) has been utilised (48, 50, 51). 
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Retrospective studies demonstrating 97% sensitivity in detection of PNS (106/109) by 
Warren et al. (2016) and 100% (30/30) by Gandhi et al. (2011) with the latter study 
successful in correctly identifying the extent of cancer spread, with a 1.5T magnet, in 
83.3% (25/30) of cases whilst underestimating proximal tumour in 13.3% (4/30) of cases 
(50, 52). A more recent study utilising targeted 3T MRI demonstrated 95% sensitivity 
(36/38) and 84% specificity (16/19 uninvolved nerves correctly detected) and correctly 
identifying cancer extent of spread in 89% (32/36) (53). However, true sensitivity and 
specificity require large prospective cohorts including a sizeable number of healthy 
individuals in additional to patients with disease. 
 
Table 1.1 Zonal classification of perineural spread of cutaneous squamous cell 
carcinoma of the head and neck 
Nerve Zone 1  Zone 2 Zone 3 
V1 (Opthalmic) To the superior 
orbital fissure 
To the Gasserian 
ganglion cistern 
Proximal to the Gasserian 
ganglion, into the cistern 
or brainstem 
V2 (Maxillary) To the external 
aperture of foramen 
rotundum 
To the Gasserian 
ganglion cistern 
Proximal to the Gasserian 
ganglion, into the cistern 
or brainstem 
V3 (Mandibular) To the external 
aperture of foramen 
ovale 
To the Gasserian 
ganglion cistern 
Proximal to the Gasserian 
ganglion, into the cistern 
or brainstem 
Facial  To the external 
aperture of 
stylomastoid 
foramen 
To the lateral end 
of the internal 
auditory canal 
Proximal to the Gasserian 
ganglion, into the cistern 
or brainstem 
Adapted from Williams et al. (2001) and Gandhi et al. (2011) (50, 54). 
 
Although inferior to MRI in imaging of perineural disease, CT has received ongoing 
technological improvements in its application since its introduction into clinical practice (50, 
55). Dual-energy CT has emerged with increasing evidence in improving diagnosis of head 
and neck malignancies (55). Dual-energy CT imaging can supplement and assist in 
identifying presence of enhancement along invaded nerve and skull base foramina but its 
exact role is still to be defined (56).  
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1.4 Prognosis of perineural invasion 
In non-cutaneous malignancies such as SCCHN, pancreatic, prostate, biliary tract, gastric 
and colorectal cancers, PNI has been reported at much higher rates and predict 
significantly worse outcomes, correlating with invasiveness and higher recurrence rates in 
SCCHN specifically (14, 17, 32, 40, 57).  
 
In NMSCs, PNI is an uncommon occurrence, developing in up to 2.74% of basal cell 
carcinomas and 14% of squamous cell carcinomas (12, 45, 58). However, these figures 
originated from tertiary referral centres and may be inflated when compared to the general 
population. Interestingly, up to one-third of PNS patients presenting with clinical symptoms 
have no identifiable primary lesion of origin (27, 52). In primary cSCCHN with incidental 
PNI, nerve diameter has been correlated to outcomes with larger nerves (≥ 0.1 mm) 
associated with increased rates of metastases, local recurrence and death (35, 59). 
However incidental PNI in the absence of other risk factors for invasive cutaneous disease 
was not associated with poorer prognosis (59). 
 
Recently cSCCHN has been examined through a large systematic review by Thompson et 
al. (2016), extensively investigating studies that examine cSCCHN with PNI (60). PNI was 
associated with significantly higher recurrence rates, metastases, and disease specific 
death (60). As expected, tumours cells that have spread away from the primary and along 
the larger named trigeminal and facial nerves carry a worse prognosis (58). This was 
confirmed by another systematic review including data from our centre by Karia et al. 
(2017) comparing clinical against incidental PNI confirming clinical PNI with significantly 
greater risk of local recurrence and disease-specific death (recurrence 37 vs. 17%, 
p<0.001; disease-specific death 27% vs. 6%, p<0.001) (61). However, studies included in 
these analyses would have differing definitions of PNI as well as inherent limitations of 
data quality from retrospective and single-centred studies. Epidemiological data has 
shown the V3 branch of the trigeminal nerve was significantly associated with decreased 
survival (62). The trigeminal and facial nerves are the most commonly involved, in contrast 
to the rarely affected cervical plexus and nerves of extraocular movement (10).  
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1.5 Management of Perineural disease 
1.5.1 Current treatment 
Perineural disease is an infiltrative process with microscopic spread, thus patients with the 
discovery of incidental PNI post excision of cSCCHN should be considered for re-excision 
to ensure clear margins or radiotherapy; even more so if other high-risk factors are present 
such as male gender, large tumour size (>2cm), cheek lesion, recurrent tumour and poor 
differentiation on histology (40, 41, 63). Overall treatment goals include tumour free 
margins and the prevention of recurrence whilst maximising quality of life and minimising 
morbidity (38). 
 
There are no current standardized guidelines for the treatment of PNI or PNS with 
management of this morbid disease varying between hospitals and institutions. Treatment 
of perineural spread is multifactorial incorporating multiple disciplines, allied health, patient 
wishes, their medical comorbidities and the severity of their disease. The treatment 
strategy undertaken by our centre for PNS, utilises the zonal classification system of 
disease by Williams et al. (2001) (Table 1.1). The gold standard of care for PNS mirrors 
other head and neck malignancies with surgical resection aiming at clear margins followed 
by post-operative radiotherapy (10). Employing this system, Solares et al. (2016) 
advocates en bloc or total surgical resection with a clear margin, and/or radiotherapy for 
zone 1 and 2 disease, but in patients with zone 3 disease, consideration of palliative 
measures are recommended given the potential to spread the disease (36). Subtotal 
resection may also be beneficial in a portion of patients, but this is decided on a case by 
case basis. 
 
1.5.2 Future treatment 
Since commercialisation of monoclonal antibodies in 1986, the industry has continued to 
expand with sales revenue representing almost half of the biopharmaceutical market (64). 
Monoclonal antibodies have therapeutic use in multiple malignancies including cetuximab 
for cSCCHN (65). Targeting the epidermal growth factor receptor (EGFR), cetuximab is 
the only Food and Drug Administration approved agent for locally advanced SCCHN in 
combination with radiotherapy (65). However, there remains no targeted therapies against 
PNI specifically, with discovery impeded by a lack of mechanistic understanding of PNI. 
Recently, EGFR overexpression has been demonstrated in 90% of cSCC with PNI in 
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unpublished work by our laboratory, raising EGFR as a potential instigator and therapeutic 
target against PNI  (66).  
 
1.6 Models of Perineural invasion 
1.6.1 In vitro systems 
The investigation and elucidation of perineural pathogenesis relies on the accuracy of 
available models to mimic disease in a controlled experimental setting. Ayala et al. (2001) 
first described the in vitro use of a dorsal root ganglia (DRG) model whereby DRG 
harvested from mice were co-cultured with prostate cancer cells within a gel matrix (67). 
The DRG neurites mimicked nerve fibres and demonstrated the symbiotic nature of PNI 
whereby both tumour and neurites experienced a growth advantage when co-cultured 
(67). Since then, modifications of the DRG model have been developed including 
utilisation of an impermeable barrier, with attraction of cancer cells by nerves when the 
obstruction was removed (18). More recently, the development of microfluidic devices offer 
precise spatial and temporal control of cancer cells and neurons through their 
compartmentalisation allowing clear visualisation of cancer cell migration and screening of 
therapeutic molecules against PNI (68). Although advantageous in its establishment of a 
rigorously controlled experimental environment, in vitro systems lose the complexities in 
modelling the tumour-nerve microenvironment. 
 
1.6.2 In vivo models 
Orthotopic models whereby cancer cells are directly implanted into their target organ or 
tissue have been employed in pancreatic, prostatic and head and neck cancers 
establishing PNI in 90-100% of cases (69, 70). Heterotopic models have also been 
employed with cancer cells injected into sciatic nerves allowing functional assessment and 
imaging (71). Although successful in creating a PNI model, through iatrogenic insertion of 
disease it skips several key steps of cancer pathogenesis, and may have a functionally 
different phenotype to natural disease progression (18).  
 
In pancreatic cancer, the in vivo carcinogenesis-induced model accurately mimics human 
disease progression whilst maintaining the tumour-nerve microenvironment (72). In this 
model KPC mice contain Kras mutations, eventuating in pancreatic cancer development. 
30 
 
The cancer in this model naturally invades the nerve in the absence of iatrogenic input and 
nerve transformations can be studied as the cancer develops (18). 
 
A recent model developed by our colleagues at the Queensland Institute of Medical 
Research (QIMR) has the potential to study the pathogenesis of PNI in cSCCHN (73). In 
humans, this disease most commonly originates as a mid-face lesion invading proximally 
along the trigeminal branches. Through injections of cancer cells into the whisker bed of 
mice, perineural invasion was successfully established in the trigeminal nerve, accurately 
modelling human disease progression of cSCCHN with PNI (Figure 1.4). To our 
knowledge, this is the first animal model of PNS of cSCC.  
 
 
Figure 1.4 Sectioned slides from BalbC mouse head with tissue specific staining. 
Stains utilised were haematoxylin and eosin (H&E), cytokeratin and S100 staining for 
general tissue structure, cancer cells and nerve cells respectively. Arrows in upper panels 
demonstrate the maxillary branch of the trigeminal nerve (V2) with lower panels showing 
magnified images with tumour cell presence. Sourced from Gardiner (2016) (73).   
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1.7 Molecular mechanisms of Perineural Invasion 
1.7.1 Overview 
The capacity for nerve invasion and central spread by tumours has long been recognised, 
however the predisposition for nerve invasion and the precise mechanisms of perineural 
advancement have not been fully elucidated (10, 28). The initial theory of lymphovascular 
spread leading to PNI has since been debunked and the “low-resistance” pathway of 
spread along multiple layers of connective tissue and cells composing the nerve sheath 
has also being questioned (18). A sizeable portion of PNI theory originates from research 
of cancer neurotropism in pancreatic, prostate, gastric and other cancers, as work on 
cSCCHN is relatively scant in comparison (16, 17, 74).  
 
Building on the discovery of a nerve-tumour symbiotic relationship by Ayala et al. (2006) in 
prostate cancer, increasing observations have been made regarding nerve contribution to 
PNI pathogenesis (67). In prostate cancer patients, there were increased neuron numbers 
in prostate ganglia when compared to controls and increased nerve density in cancer foci 
(75). Additionally, autonomic innervation of tumours has also been implicated with prostate 
cancer progression halted following sympathectomy and reduced following inhibition of 
cholinergic fibres (76). Through this work, a paradigm shift has occurred from sole focus 
on cancer cells to the modern model of PNI, detailing a symbiotic relationship between 
tumour, neural and supporting cells interacting in a complex microenvironment of secreted 
neurotrophins and chemokines (14). With the implicit role of these cells and molecules in 
normal cell homeostasis and function, it is easy to imagine their adapted role in potential 
PNI pathogenesis. 
 
1.7.2 The nerve microenvironment 
Schwann cells fulfil multiple roles including myelination of peripheral nerves, nourishment 
of developing neurons and facilitation of neuronal repair post-trauma (77). The differing 
functions of Schwann cells are enabled by their capability to dedifferentiate into different 
subtypes (77). Following nerve injury, their ability to myelinate is swapped for increased 
motility and the ability to guide neuronal repair, leading to the hypothesis that physiological 
processes activated in neuronal repair are hijacked by cancer cells in PNI (77, 78). Indeed, 
Deborde et al. (2016) has illustrated Schwann cells contacting and inserting between 
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pancreatic tumour cells, and dispersing them in a neural cell adhesion molecule (NCAM) 
dependent process (78).  
 
Fibroblasts are crucial in the peripheral sheath, not only producing growth factors and 
chemokines, but ultimately in the generation of the perineurium (79). If malfunctioning, 
perineural integrity may be compromised leading to a decreased barrier against PNI. 
Additionally, fibroblasts have increasingly been implicated in carcinoma initiation 
secondary to paracrine stimulation by fibroblast-derived growth factors (80). However, no 
direct link has been established between fibroblasts and PNI yet. 
 
With regards to the immune system, macrophages have been associated in tumour 
progression and invasion, with endoneurial macrophages implicated in the induction of PNI 
of pancreatic adenocarcinoma through glial-derived nerve factor (GDNF) and RET 
activation (81). Lymphocytes are also present in the perineural tumours with B and T cell 
infiltrates detected in over half of patients with cSCCHN (82). Galectin-1 positivity (an 
immunosuppressant) within these infiltrates was a prognosticator for poor outcome (82). 
Together these studies demonstrate the significant interactions of the tumour 
microenvironment in PNI pathogenesis (Figure 1.5). 
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Figure 1.5 The tumour-nerve microenvironment. Schematic showing a preneoplastic 
lesion (a) with nerve growth and gradual recruitment of macrophages, Schwann cells and 
Stellate cells (b, c) leading to the perineural tumour environment seen (d). Sourced from 
Amit et al. (2016) (83). 
 
1.7.3 Neurotrophins and PNI 
Neurotrophins are a family of proteins involved in neuronal development and proliferation 
with implications in survival signalling in multiple cancers (34, 84). Included in this family 
are GDNF, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT3) and neurotrophin 4 (NT4) (84). With the exception of GDNF, when 
cleaved by proteases, these neurotrophins activate their respective receptor tyrosine 
kinases or tropomyosin receptor kinases (Trk) (Figure 1.6). Downstream activation of 
these receptors leads to both axonal and neurite growth in normal physiology, particularly 
in sensory neurons, and tumour survival and proliferation in pathology (85). Interestingly, 
epidermal growth factor (EGF) has the ability to activate TrkB and TrkC receptors in 
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embryonic mice illustrating a ligand independent pathway in new-born mice and the 
importance of extracellular factors for neuronal differentiation (86). 
 
From a meta-analysis (n=16) looking at neuropeptide expression in SCCHN, Scanlon et al. 
(2015) demonstrated only galanin and BDNF were significantly different in expression to 
normal tissue and correlated to reduced clinical outcomes, although the PNI status of 
these specimens were not mentioned (34). Galanin is a neuropeptide expressed on 
peripheral nerves post-injury and has proliferative effects on SCC (87, 88). Secreted 
galanin bind to its receptor GALR2 and initiate T-cell mediated neurogenesis in nearby 
nerves, potentially contributing to PNI (34). 
 
NGF together with its receptor TrkA have been implicated with PNI in breast, pancreatic 
and prostate carcinomas (74). A more recent study of NGF and its receptor TrkA showed 
higher expression in oral tongue SCC with PNI than without (n=21 with PNI, n=21 without; 
p=0.001 and p=0.039 for NGF and TrkA respectively) (89). In adenoid cystic carcinoma 
(ACC), NGF and TrkA also strongly correlated with PNI and was also raised as a potential 
biomarker (90). When TrkA receptors were blocked in breast cancer, a significant 
reduction of breast cancer was seen, and when injecting antibodies against NGF, success 
in prevention of pancreatic and prostate cancer was seen (91). One of the few studies to 
investigate the role of TrkA in PNI and cSCC was Chen et al. (2018) demonstrating TrkA 
expression in 43% of clinical PNI specimens (21 SCC, 2 BCC) (92). Chen-Tsai et al. 
(2004) also illustrated increased staining of PNI-positive SCC tumours compared to PNI 
negative tumours (4 cSCC with PNI, 3 cSCC without PNI), however a low sample size and 
a lack of quantitative analysis detract from these results (93). A second study of cSCCHN 
by Frydenlund et al. (2015) demonstrated TrkA expression to be significantly higher 
(p=0.01) in cSCCHN (n=57) over cSCC from elsewhere (n=53) although there was a lack 
of statistical difference in PNI between these groups (94).  
 
Of the remaining neurotrophins, BDNF has been examined in ACC, gastric cancer and 
pancreatic cancer with some studies correlating increased BDNF levels of expression with 
PNI (95-97). When examined in vitro, BDNF overexpression leads to increased invasion 
and growth of pancreatic and gastric tumour cells (95, 98). When examining its receptor, 
TrkB overexpression in pancreatic ductal carcinoma has been associated with PNI (99). 
Ketterer et al. (2003) also found increased NT3 and NT4 expression in tumour cells and 
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normal nerves compared to normal pancreatic tissue (97). NT3 and its reciprocal receptor 
TrkC were greater expressed in PNI nerves within pancreatic cancer specimens and when 
NT3 was blocked, pancreatic cancer growth was halted in mice models (97, 98). More 
research needs to be done investigating the potential PNI mechanism for neurotrophins. 
 
 
Figure 1.6 Neurotrophins and their affinities for their respective receptors Receptors 
include tropomyosin related kinase A (TrkA), tropomyosin related kinase (TrkB), 
tropomyosin related kinase (TrkC) and P75. Nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4) all have high 
affinity to P75 in their unprocessed form, whilst the processed ligands have a higher 
affinity for specific Trk receptors. Sourced from Segal (2003) (100). 
 
 
1.7.4 GDNF and PNI 
The GDNF family of neurotrophins includes 4 members: GDNF, artemin, neurturin and 
persephin which all signal through an glycosyl-phosphatidylinostol-anchored GDNF family 
receptor-α (GFRα) to RET receptor complex and are secreted by nerves and supporting 
cells (18). Downstream pathways activate mitogen-activated protein kinase (MAPK), 
ultimately controlling cell migration and growth (101). There is extensive literature 
investigating the role of GDNF in pancreatic cancer with overexpression of GDNF and 
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RET seen (102). When studied in vitro, cancer cells were seen to chemotactically attract 
down an GDNF gradient with blockage of RET receptors limiting the extent of nerve 
invasion (71). Artemin, a member of the GDNF neurotrophin family was shown to be 
overexpressed along with its receptors GFRα3 and RET in pancreatic adenocarcinoma 
(103). Interestingly, artemin levels are also elevated in pancreatitis suggesting an adapted 
role from repair and inflammation to cancer proliferation and invasion (104). Overall this 
family has yet to be adequately studied in its relation to PNI of cSCCHN and may serve as 
a potential therapeutic target in future. 
 
1.7.5 Cellular adhesion molecules 
Expressed on cell surfaces of neurons and Schwann cells and important in cell adhesion 
in addition to growth, NCAM has conflicting evidence of its role in PNI. NCAM 
overexpression has been shown in prostate cancer and detected with PNI (105). 
Additionally it has been linked to Schwann cell induced insertion and dispersion of cancer 
cells as discussed previously (78). When investigated in ACC, it was highly expressed in 
all tumours regardless of PNI status (106). However, in cSCCHN, NCAM was unable to 
predict PNI in a recent study by our centre utilising clinical PNI specimens against normal 
nerves (n=14) (107).  
 
1.7.6 Chemokines 
Chemokines can induce migration or chemotaxis of target cells towards these molecules 
and are established in cancer pathogenesis (108). Monocyte chemotactic protein 1 (CCL2) 
is one chemokine that recruits monocytes expressing its CCR2 receptor during 
inflammation and has a significant function in nerve repair following injury within the PNS 
(109, 110). Additionally, evidence has emerged illustrating CCL2-CCR2 signalling  
mediating prostate tumour cell migration and nerve invasion (111). Another chemokine, 
fractalkine (CX3CL1), functions through its receptor CX3CR1 (112). Highly correlating in 
pancreatic cancers with PNI, CX3CL1 attract cancer cells in vitro and CX3CL1 transfected 
pancreatic cells invade local nerves (112). Prostate cancers that have innate high rates of 
PNI also have elevated levels of CX3CR1 (113). Recently from 28 specimens of PNS from 
a mixture of cSCC and ACC, chemokine receptor 4 was shown to be overexpressed in 
60% of stained specimens, highlighting a potential role as a biomarker or therapeutic 
target for PNS (114).  
37 
 
 
1.7.7 Axonal guidance molecules 
Ephrins are one class of axonal guidance molecules that function in cellular adhesion and 
migration culminating in neurodevelopment with normal physiology, and implicated in 
tumourigenesis and metastasis when dysregulated (115). These predominantly 
membrane-bound proteins bind to one of nine EphA and five EphB receptor tyrosine 
kinases in humans and function in cellular adhesion and migration (116). In ACC, elevated 
messenger ribonucleic acid (mRNA) of EphA2 and ephrinA1 were discovered when 
compared to normal gland tissue as well as correlating with tumour invasiveness and PNI 
(117). In the majority of SCCHN, EphB4 is highly expressed (118). However, in cSCC, 
EphB2 is overexpressed compared to normal skin and EphB2 knockout leads to inhibition 
of human SCC cell invasion. Additionally another receptor EphA1, is downregulated in 
advanced cases of cSCC, illustrating the complexity of this class of molecules (119, 120). 
Logically the ability to guide neurons raises their potential in PNI. Recent work by our 
laboratory has shown Ephrin/Eph expression in cSCCHN with PNI to be variable although 
their role in PNI cannot be excluded and may interact with other drivers of cancer (66).  
 
1.7.8 Extracellular Matrix 
A family of endopeptidases known as Matrix metalloproteinases (MMP) function through 
remodelling of extracellular matrix (ECM) (121). In peripheral nerve sheaths, collagens 
such as collagen IV are essential components of basement membranes and structural 
integrity which can be broken down by MMPs (121). NGF and GDNF have been shown to 
stimulate MMP2 and MMP9 production respectively, theoretically weakening the nerve 
sheath and facilitating PNI (122, 123). MMPs have also been overexpressed by pancreatic 
tumours, a well-known cancer with a high propensity for PNI (124). Although logically 
promising, MMP inhibitors have failed to show efficacy against tumour enlargement in 
clinical trials (125). 
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1.8 EGFR and its role in PNI 
1.8.1 EGF family of peptides and their receptors 
The ErbB receptor tyrosine kinase family includes four closely related receptors: EGFR 
(ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) (126). Agonists to this family of 
receptors form the EGF family of proteins and include EGF, epiregulin, neuregulin, 
transforming growth factor alpha (TGFα), amphiregulin, betacellulin and heparin-binding 
EGF-like growth factor (HB-EGF) (Table 1.2) (127, 128). These ligands function selectively 
with different agonists stimulating differing biological responses whilst binding the same 
receptor, hypothesized due to being secondary to different sets of tyrosine phosphorylation 
during receptor activation (127). 
 
There is a physiological role for ErbB family members in almost all cell types (129). In 
embryogenesis, they are critical with absences causing lethality in the embryonic or 
perinatal setting (130, 131). EGFR null mice develop abnormalities in multiple organs such 
as brain, lung, gastrointestinal tract and skin (132, 133). ErbB2, ErbB3 and ErbB4 mice 
develop neuronal abnormalities, neuropathies and improper brain maturation respectively, 
in additional to all developing significant cardiac defects (134, 135). Specifically ErbB2 is 
crucial in the development of sensory and motor neurons as well normal Schwann cell 
function (136). In breast, ErbB2 is widely recognised as a driver of breast cancer with 
targeted therapies developed and successful in a portion of these carcinomas (131). 
EGFR knockout mice have deficiencies in cell proliferation and migration with resulting 
degeneration of brain centres. Additionally, mice lacking EGF family ligands have a 
significantly less severe phenotypical deficit than EGFR null mice highlighting significant 
redundancy built into EGFR signalling (133).   
 
1.8.2 Epiregulin and Neuregulin 
Epiregulin binds to EGFR and ErbB4, but also stimulate signalling of ErbB2 and ErbB3 
through receptor heterodimerisation with normal physiological effects of cell proliferation, 
tissue inflammation and would healing (137). Epiregulin expression has been linked to 
bladder, gastric, colorectal, breast and head and neck cancer. When comparing mRNA 
between oral SCC (n=39) and normal oral mucosa (n=7), greater epiregulin expression 
was linked to more aggressive disease and worse outcomes (p<0.05) (137).  
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Neuregulins represent the largest subclass of the EGFR family of growth factors (138). 
Synthesised from four different genes NRG1 to NRG4, splicing of these mRNA products 
create the variety of isoforms (139). Similar to other growth peptides, functions include 
proliferation, growth, differentiation and migration (138). In vivo studies of breast cancer 
illustrate mice overexpressing mammary neuregulin result in adenocarcinoma formation 
and metastasis (140, 141). Neuregulin indirectly activates the HER2 receptor through 
ErbB3 and ErbB4 homo and or heterodimer interactions (138). Not surprisingly a certain 
subset of breast cancer tumours express neuregulin and has been proposed as a 
biomarker of anti-HER3 treatment susceptibility (142). Although scant evidence regarding 
epiregulin and neuregulin expression in cSCCHN has been observed, their role in ErbB 
receptor activation may directly or indirectly lead to tumour pathogenesis. 
 
 
Table 1.2 Selectivity of different Epidermal Growth Factor family ligands against 
their corresponding receptors 
Growth Factor                                           Binding Receptor   
EGFR ErbB2 ErbB3 ErbB4 
EGF + - - - 
Epiregulin + - - + 
Betacellulin + - - + 
HB-EGF + - - + 
Neuregulin 1β - - + + 
Neuregulin 2β + - + + 
Ligands include epidermal growth factor (EGF), epiregulin, betacellulin, heparin binding 
EGF-like growth factor (HB-EGF), neuregulin 1β  and neuregulin 2β. Adapted from Riese 
et al. (2015). (137) 
 
1.8.3 EGFR and skin development 
Neurons and their supporting glial cells develop from the ectodermal layer, whereas the 
skin derives from both ectodermal cells forming the epidermis, and mesodermal cells 
forming the dermis and hypodermis with associated connective tissue (143, 144). The skin 
is extensively innervated and enables the skin to function normally in sensation of pain, 
temperature, pressure and vibration (136). In the skin, normal EGFR signalling leads to 
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proliferation and a healthy epithelium (145). However, a wide variety of phenotypes of skin 
epithelial cells occur such as abnormal differentiation, hyperproliferation, poor regulation of 
healing and inflammation, and tumorigenesis with dysregulation (146). When EGFR null 
mice were examined postnatally, a decreased density of neurons with abnormal cutaneous 
innervation of dorsal skin was observed. However only dorsal cutaneous neurons were 
affected, excluding the trigeminal ganglia that innervate the face (136). 
 
 
Figure 1.7 Ligands of the epidermal growth factor family and downstream signalling 
pathways. Notable signalling pathways such as the mitogen-activated protein kinase 
(MAPK) cascade, Ras-Raf-MEK-ERK pathway, the phosphatidylinositol 3-kinase-Akt 
pathway (PI3K-AKT), PLCγ and JAK-STAT pathways are seen. Sourced from Yarden & 
Sliwkowski (2001) (147). 
 
1.8.4 EGFR structure and signalling 
As the prototypical ligand of the EGF family, EGF is widely expressed, binding to its 
receptor EGFR in multiple tissues functioning in cell differentiation, proliferation on a 
cellular level leading to wound healing and tissue repair (148). EGFR is a 170kDa 
transmembrane glycoprotein and member of the ErbB receptor tyrosine kinase family 
(149). Structurally, EGFR contains an extracellular ligand binding domain connected to a 
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cytoplasmic tyrosine kinase via a transmembrane portion (145). When bound and 
activated by its ligands, EGFR undergoes structural alterations seeking to pair with a 
second ErbB molecule to form homo or heterodimer complexes (149). Facilitated by 
dimerization, the tyrosine kinase can initiate downstream signalling pathways through 
phosphorylation of the tyrosine residues of its dimer (150). Regardless of the initial ligand, 
the phosphorylated ErbB partner is the key determinate of subsequent signalling (150).  
 
These signalling pathways are complex and extensively characterised in the literature 
(149, 151, 152). Archetypal pathways include the MAPK cascade, Ras-Raf-MEK-ERK 
pathway, the phosphatidylinositol 3-kinase-Akt pathway (PI3K-AKT), PLCγ and JAK-STAT 
pathways (Figure 1.7) (129). Following activation, through a dynamin mediated process, 
receptors are internalised into clathrin coated vesicles and can be broken down in 
lysosomes or recycled back to the surface (153). When functioning normally these 
pathways lead to cell proliferation and differentiation, but are implicated in anti-apoptotic 
processes, and tumorigenesis when dysregulated (145).  
 
1.8.5 EGFR overexpression in malignancies 
Up to seven distinct mechanisms of EGFR pathogenesis in cancer have been described. 
These include constitutively activated mutations, loss of regulatory mechanisms, 
transactivation through G-protein coupled signalling, gene amplification and ligand or 
receptor overexpression (126). EGFR dysregulation and overexpression is a common 
theme in roughly one third of epithelial malignancies including SCCHN, breast, colorectal, 
ovarian, pancreatic, prostate, glioblastoma, and non-small cell lung cancer (NSCLC) with 
the magnitude of EGFR overexpression correlating to cancer growth and invasiveness  
(126, 154). In cSCC, EGFR overexpression has been detected in 35% (33/94) of primary 
lesions and up to 47% (7/15) of nodal metastases (155, 156). Other studies have 
illustrated EGFR overexpression in primary cSCC to be up to 56% (28/50) (157). EGFR 
overexpression was also associated with poor prognostic implications, portending tumour 
proliferation, locoregional, and lymphatic spread as an independent factor (155). PNI is a 
form of metastasis whereby tumour cells infiltrate nerves, but this has not been well 
characterised for EGFR expression. To our knowledge, our laboratory was the first to 
demonstrate EGFR overexpression in 90% (18/20) of cSCCHN with PNS (66). 
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1.8.6 EGFR as a therapeutic target 
Due to its high significance in cancer signalling, specific anti-EGFR targeted therapies 
have emerged including two major classes: monoclonal antibodies and tyrosine kinase 
inhibitors (TKIs) (129). The first class utilises humanised antibodies functioning directly 
against the extracellular EGFR domain to prevent ligand binding and downstream 
signalling as well as indirectly, through induction of antibody-dependent cell cytotoxicity 
(ADCC) (122). Current EGFR monoclonal antibody include panitumumab and cetuximab, 
with cetuximab adapted from its initial role for metastatic EGFR positive colorectal cancer, 
into advanced SCCHN and recurrent metastatic SCCHN (123). TKIs function as 
adenosine triphosphate (ATP) mimics, excluding ATP binding and thus, halting 
downstream signalling (129). 
 
1.9 Genomic profiling in perineural invasion 
Significant research has focused on genomic data on cSCC, highlighting roles of multiple 
cancer-associated genes: p53, NOTCH1 and RAS (158).  However, there has been a 
paucity of research investigating genes implicated in PNI or PNS. Recent whole genome 
profile expression has been performed by our colleagues at the QIMR in a comparative 
analysis of cSCCHN, cSCCHN with microscopic PNI and cSCCHN with PNS. Analysing 
the genes discovered to have differential expression between the groups, p53 was 
recognised to be activated in tumours with PNI compared to those without (159). Further 
immunohistochemistry (IHC) staining revealed a diffuse over-expression pattern of p53 
implicating its dysregulation in cSCCHN with PNS (159). Using the same microarray 
expression profile dataset by Warren et al. (2016), Zheng at al. (2018) identified further 
autophagy-related genes associated with cSCCHN with PNI such as HIF1A, MAPK8, 
mTOR, BCL2L1 and RAB23. All are potential therapeutic targets in cSCC with PNI (160).  
 
An earlier study by Mays et al. (2015) analysed expression differences between cSCC 
specimens with and without histopathological PNI. However, no significant pathways were 
identified from the 24 genes identified as having significantly different expression between 
the two groups (161). One limitation of genomic analysis is that it excludes regulation at 
the RNA and protein expressing levels which can be captured by proteomics and may 
explain the absence of neurotrophins, axon guidance molecules and other factors 
implicated in PNI. Utilising sequential window acquisition of all theoretical mass spectra 
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(SWATH-MS) analysis, proteomes (library of all the proteins produced by a cell, tissue or 
organism) can be generated and compared between cSCCHN with and without PNI to 
discern if EGFR and related or unrelated molecular differences are associated with PNI. 
This is an avenue of research our unit will aim to explore in the near future.   
 
1.10 Immunotherapy in malignancy 
The use of immunotherapy in the treatment of cancer has steadily evolved over past 
decades (162). The current dogma includes the targeted inhibition of key immune system 
components whilst maximising efficacy and minimising toxicity (163). The evasion of the 
immune system by cancer cells is a fundamental feature of tumour proliferation and 
survival (164). Mechanisms of immune evasion include downregulation of tumour 
antigens, upregulation of immunosuppressive factors and production of anti-inflammatory 
cytokines (163). Checkpoint inhibitors are one such example of the expanding breadth of 
immunotherapy. 
 
The normal immune system operates through a complex interplay between the 
identification and elimination of foreign pathogens and the prevention of a self-harming 
response (165). Interaction between co-stimulatory and co-inhibitory ligand and receptors 
form checkpoints that regulate the immune response and are potential targets to counter 
cancer evasion (162). Three such therapeutic targets include programmed cell death 
protein 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte 
associated protein 4 (CTLA-4) (166). PD-1 and PD-L1 have had significant interest and 
investment undergoing exploration in hundreds of clinical trials with the development of 
anti PD-1 therapies such as nivolumab, pembrolizumab and cemiplimab, and anti PD-L1 
therapy such as atezolizumab, avelumab and durvalumab (167, 168). 
 
1.10.1 PD-1 and PD-L1  
PD-L1 is normally present on antigen presenting cells as well as tumour cells, whereas 
PD-1 receptors are present on activated lymphocytes (163). The immunosuppressive 
effect of PD-1 activates when bound by its ligand PD-L1, which is produced by somatic 
cells in response to inflammation (169). In addition to PD-L1, CD273 or programmed death 
ligand 2 (PD-L2) also binds to PD-1 with activation leading to downstream signalling 
through tyrosine phosphatase SHP-2 by a dephosphorylation cascade (Figure 1.8) (167).  
44 
 
 
Figure 1.8 Signalling of programmed cell death protein 1 (PD-1) pathway and its 
mechanism of inhibition. T cell receptor binding by major histocompatibility complex 
(MHC) leads to T cell activation and production of interferon (IFN). This activates JAK1/2 
signalling with phosphorylation and activation of STAT proteins ultimately inducing surface 
expression of programmed death ligand 1 (PD-L1). Increased expression of PD-L1 
inactivates other T cells currently active against tumour cells. Therefore, inhibition of this 
ligand-receptor interaction results in proliferation and activation of T cell cytotoxicity 
against tumour cells.    
 
 
Nishimura et al. (1999) initially discovered PD-1 as a negative immune regulator through 
work with in vivo PD-1 deficient mice whilst Dong et al. (1999) was first to describe PD-L1, 
then known as B7-H1 (170, 171). PD-L1 tumours have shown expression in head and 
neck, haematological, gastrointestinal, lung, ovarian, bladder, renal and melanoma 
cancers (163). Tumours are hypothesized to express PD-L1 secondary to genetic defects 
and activation of oncogenic pathways or in response to tumour infiltrating lymphocytes 
(TIL) as an resistance mechanism (172). Mice deficient in PD-1 were also demonstrated to 
inhibit tumour growth and when expressed on tumour cells, PD-1 was associated with 
tumour invasion and metastases with blockage of this pathway causing anti-tumour effects 
(173). When two independent checkpoints PD-1 and CTLA-4 were blocked, tumour was 
seen to be rejected in mice, highlighting a synergistic potential for combination of PD-1 
inhibition with independent pathways (174, 175). 
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The association between viral infections and certain head and neck cancers have been 
established and rationalises the potential for immune checkpoint therapy to be effective in 
this disease population. Human papilloma virus (HPV) positive SCC has better prognosis 
than HPV negative SCC with presence of HPV expression related to presence of TIL 
(176). Additionally, HPV positive tumours are more likely to express PD-L1 and the 
presence of PD-1 positivity in TIL of HPV positive SCCHN relates to prognostic benefit 
(177, 178).   
 
1.10.2 Monoclonal antibody therapy against PD-1 and PD-L1 
PD-1 and PD-L1 are obvious targets of checkpoint inhibition. Inhibition of PD-1 may block 
all potential ligands including PD-1 and PD-L2 and is theorised to increase efficacy, with 
the detriment of increasing toxicity when compared to PD-L1 blockade (163). Response to 
anti PD-1 treatment was first illustrated in 2006 where 37.5% of patients (n=16) who 
received nivolumab demonstrated tumour responses amongst NSCLC, melanoma and 
renal cell carcinoma patients (179). Since then, the evidence accumulated from objective 
tumour response data has led to the six Food and Drug Administration approved 
monoclonal therapeutic antibodies we see today for advanced cSCC, Hodgkin’s 
lymphoma, melanomas, Merkel cell carcinoma, NSCLC, SCCHN, gastric cancer, urothelial 
carcinoma, renal cell carcinoma and hepatocellular carcinoma (Table 1.3). 
 
 
Table 1.3 Main indications for use of anti-programmed cell death protein (PD-1) and 
anti-programmed death-ligand (PD-L1) therapies 
Checkpoint inhibitor Target Indication 
Avelumab PD-L1 Merkel cell and Gastroesophageal 
Atezolizumab PD-L1 Melanoma and Gastroesophageal 
Cemiplimab PD-1 cSCC 
Durvalumab PD-L1 Urothelial  
Nivolumab PD-1 SCCHN, Hodgkin Lymphoma, 
melanoma, NSCLC, Urothelial, RCC 
and hepatocellular 
Pembrolizumab PD-1 SCCHN Hodgkin’s Lymphoma, 
melanoma, Merkel cell, NSCLC, 
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gastroesophageal, urothelial and RCC 
Cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma 
(SCCHN), non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Adapted 
from Ribas & Wolchok (2018) and Hargadon et al. (2018) (167, 180). 
 
 
When treated with nivolumab, carcinogenic related cancers such as SCCHN were 
demonstrated to have a significantly higher response rate when compared to standard 
single-agent treatment of methotrexate, docetaxel or cetuximab (13.3% with nivolumab 
against 5.8% with standard therapy) in addition to significantly longer overall survival 
(Median survival 7.5 months nivolumab against 5.1 months with standard therapy; p=0.01) 
in recurrent SCCHN (n=361) (181). Until very recently, no systemic immunotherapies had 
been approved for the treatment of advanced cSCC and in the context of accumulating 
evidence of checkpoint inhibitor efficacy, cemiplimab was approved for this indication. 
When treated with cemiplimab, a non-randomized phase 2 study illustrated a 47% 
response rate (28/59) of advanced cSCC patients (168).  
 
Although no trials has yet to investigate anti-PD-1 or anti-PD-L1 therapy in perineural 
disease, it has been established by our group that perineural SCC contains a noticeable 
CD8 T cell population with PD-1 and PD-L1 expression within and surrounding perineural 
tissue (182). Therefore, these tumours have the potential to respond to checkpoint inhibitor 
therapy and through the augmentation of current cancer regimens with developing 
immunotherapies, previously untreatable cancers such as PNS of cSCCHN may soon 
receive required therapeutic options.  
 
1.10.3 Challenges of current checkpoint therapy 
Firstly, assessing treatment response can be difficult due to a phenomenon known as 
tumour flare or pseudo-progression where transient worsening of current lesions or 
development of new lesions can occur in 10% of patients undergoing checkpoint inhibition 
(183). The majority of clinical trials utilise the Response Evaluation Criteria In Solid 
Tumours (RECIST) to evaluate clinical responses (163). But given the occurrence of 
pseudo-progression, many investigators opt to use the Immune-Related Response Criteria 
(IRRC) which allows for transient worsening in clinical response (163)  
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The lack of standardized protocols for the assessment of PD-L1 expression makes it 
difficult to compare results. Currently, IHC is the most utilised tool to assess PD-L1 
expression, but a spread of differing expressions was seen using different antibodies as 
well as analysing fresh frozen (FF) and formalin-fixed paraffin embedded (FFPE) 
specimens (184, 185). Complicating matters, different tumours from the same patient can 
demonstrate disparate PD-L1 expression (163). Finally, PD-L1 expression is dynamic and 
can be influenced by prior treatments. Despite these issues, the analysis of PD-L1 IHC 
expression using Tumour Proportion Score (TPS) is widely accepted in lung cancer with 
thresholds for positivity specific to each monoclonal antibody. 
 
2 Experimental rationale 
Currently no targeted therapy exists to combat PNI of cSCCHN in the context of a lack of 
definitive mechanistic understanding of the molecular processes by which PNI develop. It 
is established in the literature that cSCC has approximately 45% overexpression of EGFR 
while SCCHN is 98% EGFR overexpressing. Our laboratory has found that PNS, a form of 
metastasis of cSCCHN, is 90% EGFR overexpressing (Figure 2.1). It is unclear whether 
cSCC with higher EGFR expression are predisposed to nerve infiltration or if the process 
of nerve invasion leads to EGFR overexpression. Given the presence of PD-1 and PD-L1 
expression in PNS of cSCCHN there is also potential for checkpoint inhibitors precipitating 
a beneficial tumour response (182).  
 
Through further investigation of identified primary cSCC lesions that are known to develop 
PNS and through novel methods of employing in vitro models such as combining the 
popular DRG-matrigel model with the microfluidic chamber system, we aim to better 
understand the molecular mechanisms of PNI.  
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Figure 2.1 Epidermal growth factor receptor overexpression in different squamous 
cell carcinoma groups.  Schematic demonstrating different forms of squamous cell 
carcinoma (SCC) and their proportion of epidermal growth factor receptor (EGFR) 
overexpression. Cutaneous SCC with perineural invasion (PNI) demonstrates an 
overexpression of EGFR twice that of cutaneous SCC indicating its role as a molecular 
discriminator and suggesting a role in PNI.  
 
 
3 Hypothesis 
I hypothesise that migration of cSCC cells in PNI may be due to the chemotactic function 
of EGFR, as per its developmental role.  
 
Due to the expansion of immunotherapy in anti-tumour therapy, immune mediators such 
as PD-1 and PD-L1 may also be promising therapeutic targets in PNI.  
 
Hypothesis is based on the data that approximately 45% of cSCC overexpress EGFR but 
over 90% of cSCC with PNS overexpress EGFR, and the recent success of 
immunotherapy in recurrent SCCHN and melanoma. 
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4 Aims 
1) To test the hypothesis by analysing index tumours from patients with PNS by 
histology and molecular marker imaging to define whether all PNI arises from EGFR 
high tumours or whether EGFR expression is upregulated as cSCC cells invade 
along nerves. 
2) To investigate potential therapeutic targets such as HER2, PD-1 and PD-L1 by 
histopathological staining of primary cSCCHN identified as later causing PNS. 
3) To establish in vitro and in vivo models to test the function of EGFR and its ligands 
in PNI and to test anti-EGFR combination therapy as a potential targeted 
therapeutic option for PNI patients who fail surgery and radiotherapy. 
 
5 Materials and methods 
 
5.1 Ethical clearance 
Institutional ethics approval was obtained at the Princess Alexandra Hospital (PAH) and 
Metro South Health Human research ethics committee (HREC) and amended to cover the 
scope of this research (HREC/03/QPAH/197) (appendices 10.1). Patient informed written 
consent was obtained prior to commencement of research (appendices 10.2). Eligible 
patients were selected from a secure database tracking the clinical information of 
individuals treated for any perineural malignancy of the head and neck at PAH. The 
password protected database include clinical details such as histology of primary and PNS 
lesions, imaging results, treatment undertaken and outcomes.  
 
Animal ethical approval was obtained to cover the scope of the research (UQDI/456/17 
and UQDI/359/17) (appendices 10.3, 10.4). 10 NSG-A2 mice (5 male and 5 female) aged 
6-8 weeks old were obtained from the colony of Associate Professor Kristen Radford at the 
Translational Research Institute (TRI) and used in the establishment of a pre-clinical in 
vivo model. NSG-A2 mice were selected specifically for their immunodeficiencies. Once 
established, future extensions of the in vivo model can assist in investigation of the 
significance of the immune response through introduction of peripheral blood mononuclear 
cells. Adult Balb/c and C57BL/6J mice (3-4 months old) were used in the establishment of 
a non-clinical in vitro model. Mice were housed in the TRI animal facility and cared for 
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according to standard protocol and The Code. Experimental procedures were performed 
with aseptic technique in accordance with standard operating protocols.  
 
5.2 Tissue acquisition 
Tumour samples were obtained from Australian pathology services, de-identified and 
assigned with a unique tracking code secured in a password protected database to 
facilitate review of clinical information. All tumours were stored as Formalin Fixed Paraffin 
Embedded samples and further IHC and immunofluorescence (IF) was performed on 5μm 
sectioned charged slides. All tumour blocks were stained with haematoxylin and eosin 
(H&E) to confirm the presence of SCC and secondarily validated by an accredited hospital 
pathologist. FFPE tumour blocks were located and obtained from 34 patients conforming 
to eligibility criteria described below.  
 
Inclusion criteria necessitated adult patients with a histopathological diagnosis of PNS 
originating from cSCCHN. Patients must have had a previous cSCC excised and only 
patients with previous cSCCHN located in the region correlating with clinical signs, 
symptoms and imaging of PNS were included in further analyses (e.g. forehead cSCCHN 
in a patient with later ophthalmic nerve perineural disease on MR neurogram). Specimens 
originating from patients with multiple SCCHN within the same area were excluded (e.g. 
multiple forehead cSCCHN lesions from the same patient). These previously excised 
cSCC lesions of the head and neck were identified as the primary or index lesion leading 
to later PNS. Protocols were carried out in accordance with the Helsinki declaration. 
 
As per HREC/03/QPAH/197, prospective tissue collection was also performed with patient 
consent from individuals undergoing excisions of cSCCHN with PNS. 13 Small 5-10mm 
samples of nerve-invaded tumour were taken at time of surgery and fresh frozen in minus 
80°C. Normal nerve was also sampled if a suitable portion was resected with the surgical 
specimen. All samples were confirmed on histopathology for SCC within the nerve. Future 
work will aim to utilise Sequential Windowed Acquisition of All Theoretical Fragment Ion 
Mass Spectra (SWATH-MS) technology to compare the proteomic signatures in cSCCHN 
with and without PNI.       
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5.3 Antibodies 
Numerous primary antibodies were sourced and utilised at different concentrations for 
Western blot, cell immunofluorescence and IHC tabulated below (Table 5.1). Clinically 
verified and pre-diluted antibodies for the Ventana Discovery automated staining system 
were obtained and utilised as per hospital pathology standard operating protocols at the 
TRI. 
 
 
Table 5.1 Source and concentration of primary antibodies used during research 
higher degree 
Antibody Clone Source Host/ 
Isotype 
Conc 
(μg/mL) 
WB 
conc. 
Cell 
IF 
conc. 
Tissue 
IHC/IF conc. 
Β-tubulin  2-28-33 ThermoFisher 
Scientific – 
Invitrogen 
Mouse/IgG1 500  1/10,000 N/A N/A 
AE1/AE3 MAB3412 Chemicon Mouse/IgG1 100  N/A 1/200 1/500 
EGFR 111.6 ThermoFisher 
Scientific – 
Invitrogen 
Mouse/IgG1 200 1/4000 1/100 N/A 
EGFR 31G7 Life Technologies Mouse 200 1/4000 1/100 1/100 
EGFR AB3/EGFR.1 Fisher Scientific Mouse/IgG1 200 1/4000 1/50 N/A 
EGFR SC120/528 Santa Cruz 
Biotechnology 
Mouse/IgG2a 200 1/4000 1/50 N/A 
HER2 4B5 Roche Tissue 
Diagnostics 
Rabbit 16  N/A N/A Pre-dilute 
PD-1 NAT105 Roche Tissue 
Diagnostics 
Mouse/IgG1 N/A N/A N/A Pre-dilute 
PD-L1 SP263 Roche Tissue 
Diagnostics 
Rabbit 1.61  N/A N/A Pre-dilute 
Β-III 
tubulin 
TUJ1 Fisher Scientific Mouse 200 N/A 1/200 N/A 
Concentration (Conc), Western blot (WB), immunofluorescence (IF), 
immunohistochemistry (IHC). 
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5.4 Cell culture 
A431, SCC9 and SCC15 cell lines were obtained from the American Type Culture 
Collection. A431 is a human epidermoid carcinoma derived from an 85 year old with 
significant EGFR overexpression (186). KJD cells are derived from normal keratinocytes 
transformed through SV40 virus (187). SCC15 and SCC9 cell lines are tongue derived 
SCC cell lines. Together they represent a range of relative levels of EGFR expression. To 
our knowledge there are no derived cell lines from cSCCHN with PNI or PNS. The KJD 
cell line was received as a gift from Professor Nicholas Saunders at the University of 
Queensland Diamantina Institute (UQDI), Australia. These four cell lines were selected on 
their innate levels of differing EGFR expression. Cells were maintained in Dulbecco’s 
Modified Eagle’s Medium: Nutrient Mixture F12 (DMEM/F12) and supplemented with 10% 
(v/v) heat-inactivated foetal bovine serum (FBS), 10mM of hydroxyethyl 
piperazineethanesulfonic acid (HEPES) and 2mM of L-Glutamine. Cells were kept in a 
humidified incubator at 5% CO2 at 37°C and all cells were split twice weekly. 
 
5.5 Western blot 
Cell lysates of KJD and A431 cell lines were prepared at 4°C with 
radioimmunoprecipitation (RIPA) lysis buffer and stored at minus 80°C. 10 μg of cell lysate 
samples and a pre-stained ladder were run on 10% SDS-PAGE gel and subsequently 
transferred to a PVDF membrane by gel electrophoresis. Primary antibodies 31G7, 
SC120, 111.6 and AB3 were diluted at 1/4000 concentration in 5% w/v Bovine Serum 
Albumin (BSA) in Tris-buffered saline with Tween 20 (TBST) and incubated overnight at 
4°C with gentle mixing (Table 5.1). Membranes were washed three times with TBST and 
horse radish peroxidase (HRP) conjugated secondary antibodies were incubated at room 
temperature for 1 hour at a concentration of 1/10000 in 5% w/v BSA in TBST. A final wash 
in TBST (3 washes) was performed and proteins were visualised using enhanced 
chemiluminescence with ChemiDoc MP Imaging System. Chemiluminescence reagents 
(Bio-Rad) and a -tubulin loading control were used. 
 
5.6 Cell Immunofluorescence 
Cell types A431, KJD, SCC9 and SCC15 were seeded on coverslips and allowed to attach 
overnight and used at greater than 75% confluency. When target density was achieved, 
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cells were washed twice with phosphate buffered saline (PBS) and fixed with 4% PFA in 
PBS for 15 minutes. Cells were then washed three times with PBS and permeabilised with 
0.01% Triton X-100 in PBS for 10 minutes. After a second triplet wash with PBS, cells 
were blocked with 2% w/v BSA in PBS for 30 minutes. Primary mouse anti-EGFR 
antibodies AB3 (1/50), SC120 (1/50), 31G7 (1/100) and 111.6 (1/100) were incubated with 
the cells overnight at 4°C (Table 5.1). After washing with 2% w/v BSA in PBS x3 for 5 
minutes, a secondary Alexa-Fluor-647 (1/200) antibody was incubated for 45 minutes with 
the cells. All staining included positive and negative cell controls including secondary 
antibody only controls. Cells were washed three more times with 2% w/v BSA in PBS, and 
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (1/10,000) for 5 minutes, and 
finally mounted on slides with Invitrogen Prolong GoId and left to dry overnight.  
5.7 Immunohistochemistry 
IHC was performed using the Ventana Discovery Ultra automated staining system. IHC for 
EGFR utilised enzymatic antigen retrieval and incubation with 31G7 anti-EGFR antibody at 
a concentration of 1/100 at 36°C for 1 hour, followed by horseradish peroxidase (HRP)-
conjugated secondary antibody at room temperature (RT) for 1 hour (Table 5.1). Staining 
was visualised with 3,3'-diaminobenzidine (DAB) and haematoxylin counterstain via the 
Ventana anti-HQ HRP automated detection system. Manual steps such as primary and 
secondary antibody incubation and mounting of coverslips were performed by the 
histology staff at the TRI. All staining included positive and negative tissue controls as well 
as secondary antibody only controls.   
 
PD-1 and PD-L1 staining was also performed using the Ventana system following hospital 
verified staining protocols. Antigen retrieval was performed with CC1 retrieval solution (pH 
8.0) at 95°C for anti-PD-1 and anti PD-L1. Pre-diluted antibodies for PD-1 (NAT105) and 
PD-L1 (SP263) were incubated with tissue for 32 minutes at 36°C (Table 5.1). Anti HQ 
HRP detection system was used with pre-dilute IgG anti-rabbit HRP-conjugated secondary 
antibodies incubated for 16 minutes hour at RT. DAB and haematoxylin counter-stain was 
performed, and slides and cover slides were mounted. Appropriate positive and negative 
controls were utilised including secondary only controls.  
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HER2 staining was completed in a similar manner using the pre-diluted antibody (4B5) 
through CC1 retrieval with primary antibody incubation for 12 minutes. Secondary anti HQ 
HRP detection antibodies were incubated for 8 minutes.    
 
5.8 EGFR Interpretation 
Analysis of EGFR IHC was performed by two blinded independent pathologists using two 
clinically validated scoring systems (188). Firstly, an index score between 0 to 400 was 
generated by multiplying the percentage of tumour cells stained (0 to 100%) by the 
dominant intensity pattern of staining graded (1 to 4) (188). Positivity was taken as any 
staining of tumour cell membranes above background levels and an index score of ≥200 
was counted as EGFR overexpression. Second, a widely utilised 4-point intensity 
histopathological scoring system (0-negative, 1-weak positivity, 2-moderate positivity, 3-
strong positivity) was utilised and required greater than 10% of all tumour cells to 
demonstrate strong staining to count as positive. Specimens scored as moderate or strong 
positivity were considered as EGFR overexpressing. It should be noted that this is a 
standardized hospital pathology scoring system. Only specimens positive in both scoring 
criteria were accepted as EGFR overexpressing for the purposes of our study. EGFR 
assessment in cSCC is not standardised and the interpretation used in this thesis is further 
discussed later. Given the laboratory data on response prediction, the scoring system for 
potential therapy combination response to dynamin/monoclonal antibody therapy by 
immunofluorescence imaging follows a different criteria to this pathology system (189).  
 
5.9 HER2 interpretation 
HER2 IHC is utilised in hospital pathology analyses. Primary cSCCHN lesions identified as 
causing later PNS were stained for HER2 and assessed by a Staff Pathologist at PAH 
using the 4-point histopathological scoring system described above.  
 
5.10 PD-1 and PD-L1 interpretation 
Immunotherapy targeting the immune checkpoints PD-1 and PD-L1 have shown efficacy 
and promise in a multitude of cancers (Table 1.3). Assessment of PD-L1 has been 
advocated as a potential marker for response to therapy, but questions remain regarding 
ideal thresholds for PD-L1 positivity given that a subset of patients respond despite low 
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PD-L1 expression (190). There are a lack of standardised protocols for assessment of PD-
1 and PD-L1 expression with IHC the most commonly utilised assessment tool to assess 
PD-L1 (184). In our study, PD-L1 expression of index cSCCHN lesions identified as later 
causing PNS was assessed using the Tumour Proportion Score (TPS), or the percentage 
of total tumour cells stained(191). The threshold for PD-L1 positivity was a TPS score of ≥ 
25%. PD-1 expression was also assessed using the TPS system in tumour cells as well as 
tumour infiltrating lymphocytes (TIL). Immune cells in the vicinity were scored with an 
immune proportion score (IPS) with the percentage of total TILs in the vicinity of tumour 
(within a 20x field of view) also scored. PD-1 and PD-L1 expression were assessed and 
scored by an independent accredited hospital pathologist. The choice of thresholds utilised 
in this thesis is discussed later.   
 
5.11 Microscopy 
IHC slides were imaged and assessed on a Nikon brightfield microscope at (x4, x10, x40 
and x100) magnifications. Immunofluorescence stained slides were examined on an 
Olympus FV3000 confocal microscope provided by the TRI Microscopy Core Facility at 
x60 utilising wavelengths for DAPI and Alexa Fluor 647. Images were processed through 
Image J and Adobe Photoshop Illustrator for Windows 10. Adjustments were made to 
brightness and contrast uniformly to optimise visualisation of staining.  
 
5.12 Subcutaneous tumour challenge of mice  
All animal handling was in accordance with regulatory requirements of the University of 
Queensland Animal Ethics Unit and The Code. Ethical clearance was obtained from the 
University of Queensland Diamantina Institute Office of Research Ethics (UQDI/456/17) 
(appendices 10.3). 
 
A431 cells transduced with lentivirus containing luciferase (Luc2) were obtained from our 
collaborators at the QIMR (Dr Glen Boyle, Australia). These cells were selected due to 
their presence of luciferase and their potential for bioluminescence. Cells were grown in 
DMEM/F12 and supplemented with heat-inactivated FBS, 10mM of HEPES and 2mM of L-
Glutamine. A humified incubator at 5% CO2 at 37°C was used for cell growth and all cells 
were split twice weekly until adequate cell numbers were obtained.  
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Once culture flasks (T75) were 75% confluent, A431-Luc2 cells were washed twice with 
PBS and detached with 0.25% Trypsin-EDTA. Trypsin was inactivated with growth media 
and the cell suspension was centrifuged at 800rpm at 4°C for 5 minutes in a falcon tube 
(15mL). After discarding the supernatant, the cells were resuspended in 2mL of PBS. A 
cell count was performed using a haemocytometer and the cell suspension was diluted to 
achieve a concentration of 100x104 cells/mL.  
 
20,000 A431-Luc2 cells contained in 20 µL of PBS were injected into the right whisker pad 
of 10 NSG-A2 mice using a 31G insulin syringe. After gaseous anaesthesia of 4% 
isoflurane to all mice, injections were administered bevel up, directing along the snout at 
roughly 20° to the horizontal to avoid direct seeding of the trigeminal branches (V2). 
Correct injection of cells into the whisker pad of the subcutaneous skin were confirmed 
with the presence of a translucent nodule. Careful monitoring of mice was performed 
during the entire duration of anaesthesia and post-operative recovery. Post injections, 
mice weight and tumour measurements were monitored thrice weekly. Digital callipers 
were used to measure tumour length and width with tumour volume calculated using the 
equation: Tumour Volume = (length x width2)/2. 
 
5.13 Primary tumour resection 
After whisker pad tumours reached between 0.2 to 0.5cm
 3 in size, surgical resection was 
performed. Mice were anaesthetised with 100mg/kg ketamine and 10mg/kg xylazine 
mixture via intraperitoneal injection technique through 25G syringes. Through this method, 
approximately 45-60-minutes of adequate anaesthesia was achieved and confirmed 
through absence of reflexes and rate of breathing. Standard sterile operating technique 
was utilised. Eye ointment was applied to prevent corneal ulceration and the target incision 
site was shaved and prepped with iodine antiseptic. Whisker pad tumours were accessed 
via a caudo-cranial skin flap. Tumour was carefully accessed and excised using blunt 
dissection with iris scissors. Significant effort was made to avoid injury to the eyes, 
nasolacrimal duct system and entry into the paranasal sinuses and nasal cavity. 
Haemostasis was achieved using diathermy and pressure. Skin incision was closed with 
Dermabond surgical glue. Post-operative analgesia was administered in the form of 
buprenorphine subcutaneously (0.05mg/kg) via a 31G needle 8-12 hourly for 48 hours. 
Post-operative fluids were also administered via subcutaneous injection of 100 µL of saline 
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twice spread over different regions of the body. Mice were monitored at least twice daily 
during this post-operative phase and allowed to recover in a ventilated cabinet within 
individual cages with easy access to softened feed and fluids. 
 
5.14 Bioluminescence imaging 
A431-Luc2 cells were seeded in a 96-well plate with consecutive 2-fold serial dilutions 
from 40,000 cells. After 4 hours for cell attachment, 200 µL of luciferin in the form of D-
luciferin potassium salt (15mg/mL) was introduced to 10mL of growth media. 100 µL of this 
mixture was added to each well to achieve a final concentration of 150 µg/mL. 
Luminescence was quantified using an IVIS spectrum optical imaging system. Total flux 
(photons/second) at each cell number was recorded.  
 
Additionally, luciferase activity and detection of luminescence within the whisker pad of a 
mouse was tested. 20,000 cells of A431-Luc2 cells were injected into the whisker pad and 
bioluminescence was analysed in a recently deceased mouse provided by the TRI animal 
facility.  
 
Post-operative bioluminescence patterns were also tested, one-week post-primary tumour 
resection, mice were re-anaesthetised with gaseous 2.5% isoflurane and injected with 200 
µL luciferin (15mg/mL). Imaging was again performed with IVIS spectrum optical system 
testing every minute for 10 minutes. 
 
5.15 Histological analysis  
After IVIS imaging, mice were euthanized using CO2 gas for at least 5 minutes. A 
transverse cut through the cervical spine permitted the heads to be separated for 
histological analysis. Mice that developed tumour masses in the neck also had these 
resected for further processing. The head and necks were transferred to 10% paraffin 
formaldehyde at 4°C for 24 hours. The heads were then transferred to 15% EDTA solution 
in 10mM phosphate butter and incubated for 4 weeks facilitating bone decalcification. 
Once complete, mice heads were rinsed with water removing EDTA before being 
processed into paraffin wax. Three transverse sections were taken at 90° to the maxillary 
division of the trigeminal nerve, at three varying distances from the tumour inoculation site 
to track the proximal extent of potential PNS. Use of H&E stains alone may not adequately 
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detect PNI and therefore cytokeratin AE1/AE3 and S100 immunohistochemistry staining 
was performed at the QIMR histology department where an extensive breadth of 
experience with this staining and processing technique was invaluable. Evaluation was 
performed by an experienced histopathologist grading presence of PNI or PNS along the 
maxillary branch of V2 towards the skull base.  
 
5.16 Dorsal Root Ganglia Harvest 
All animal handling was in accordance with regulatory requirements of the University of 
Queensland Animal Ethics Unit and The Code. Ethical clearance was obtained from the 
University of Queensland Diamantina Institute Office of Research Ethics (UQDI/359/17) 
(appendices 10.4). Adult Balb/c and C57BL/6J mice (3-4 months old) were sacrificed using 
carbon dioxide over cervical dislocation to preserve cervical DRG. DRG were extracted 
through a modified protocol of an established method (Figure 5.1). All equipment and mice 
post-euthanasia were sterilised with 80% w/v ethanol. Mice were pinned with 23G needles 
and the dorsal musculature exposed using forceps and scissors through a longitudinal 
midline incision. The vertebral column was transected at the base of the skull and pelvis 
and completely removed through parallel longitudinal excisions of all ribs and musculature. 
The freed vertebral column was washed with DMEM/F12 supplemented with FBS, L-
Glutamine, sodium pyruvate, amphotericin B, penicillin and streptomycin (anti-anti) and 
partially suspended in a petri-dish for further dissection. Micro scissors were then utilised 
for division of the vertebral pedicles allowing removal of dorsal vertebral lamina and 
musculature exposing the spinal cord. Further dissection was performed under bright-field 
microscopy using fine dissecting forceps and micro-scissors. The spinal cord was slowly 
peeled in a rostral-caudal direction with care taken to not detach the DRG below. DRG 
were visualised as flat round discs either just dorsal to the spinal cord and grabbed and 
gently removed with traction at the distal protruding axon, or at the proximal sensory 
bundle and freed with micro-scissors. The DRG were cleaned by removing excess axon 
bundles. 
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Figure 5.1 Dorsal root ganglia extraction process Upper panels (a-h) demonstrate 
removal and deliverance of spinal column from NSG and Balb/c mice. Lower panels (a-h) 
demonstrate dissection of DRG with rostral-caudal removal of spinal cord, and removal of 
excess axonal tissue. Sourced from Sleigh et al. (2016) (192).  
 
5.17 Seeding into a microfluidic chamber device and culture  
Harvested DRG were collected in DMEM/F12 with 10%FBS, L-Glutamine, sodium 
pyruvate and anti-anti, and centrifuged at 1G for 1 minute to pellet in a microtube. 
Supernatant was removed and DRG were incubated at 37°C in 2mL of Collagenase type II 
(Gibco) in F12 media for 90 minutes with gentle mixing. The suspension was triturated to 
dissociate into a cellular mixture and passed through a 70µL cell strainer followed by two 
1mL washes with DMEM/F12 and anti-anti supplemented media. The suspension was 
then centrifuged at 100G for 5 minutes to re-pellet. Supernatant was removed and washed 
with DMEM/F12 with 10% FBS with anti-anti and re-triturated to confirm dissociation into 
cells. The dissociated cell suspension (containing DRG, glial cells and unwanted debris) 
was filtered through 3mL of 15% BSA in DMEM/F12 with 10% FBS and anti-anti by gently 
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pipetting cells into a top layer above the BSA and centrifuging for 5 minutes at 1300rpm. 
Live cells reformed into a pellet with dead cells and debris remaining in the supernatant. 
The supernatant was removed, and the cell pellet was reconstituted in 5μL of neurobasal 
media and seeded in a microfluidic chamber device designed by Ms Priscila De Lima 
based off commercially available Xona chambers (Xona microfluidics, SND450) overlying 
a glass 6-well plate (Figure 5.2). Cells (neurons and glial cells) were seeded at a 
concentration between 5-8 million cells/mL.  
 
 
Figure 5.2 Microfluidic device, a scaffolding for neuronal and cancer growth. 
Neurons are cancer cells are seeded in opposite channels with a 5μm diameter 
microchannel separating them. Neurites, although not neurons are able to grow through 
these microchannels. Advantages as a rigorously controlled environment spatially and 
temporally. Sourced from Lei et al. (2016) (68). 
 
 
Cells were seeded in the neuronal channel and allowed to attach before 300μL of 
neurobasal media supplemented with FBS, L-Glutamine, sodium pyruvate and anti-anti 
was added to both the neuronal and cancer main channels. NGF at a concentration of 50 
ng/mL was added to the opposite well to encourage neurite growth prior to addition of 
cancer cells.  Neuronal cells were incubated at 37°C and 5% CO2 for 7 days. A431 cancer 
cells were added on day 7 and seeded at 2.5 x106 cells/mL on the cancer side of the 
device. Media was changed every 2 days during cell culture. Chambers were carefully 
removed and both neuronal and cancer cell populations were permitted to interact. 
Microfluidic chambers were utilised as a facilitating scaffold for cell growth and interaction. 
Experiments without removal of the scaffolds have been shown to be limiting to the overall 
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growth and migration of cultured cells due to the limited space of interconnected 
microchannels and main channels (68). 
 
5.18 DRG Cell Immunofluorescence  
Cells were gently washed twice with PBS and fixed with 4% PFA in PBS for 20 minutes. 
Immunofluorescence was then performed as per Cell Immunofluorescence (section 5.6) 
utilising TUJ1 anti-β III tubulin (1:200) and anti-cytokeratin (1:200) as primary antibodies 
for neuronal and epithelial cells respectively. Goat anti-mouse Alexa-Fluor-488 and anti-
rabbit Alexa-Fluor-594 were utilised as secondary antibodies (1:200). All staining included 
appropriate controls.  
 
5.19 DRG and A431 Live imaging interaction 
DRG harvest, seeding and culture were performed as described (materials and methods 
5.16, 5.17). However, the microfluidic chambers were carefully removed 6 hours post 
A431 seeding instead of 7 days. Cetuximab was added to the growth media to reach a 
concentration of 60μg/mL and appropriate controls were utilised including DRG and A431 
only wells. This concentration of cetuximab is the highest concentration achievable whilst 
maintaining 90-100% A431 cell viability based on previous growth-inhibition assays by our 
laboratory. Experimental groups included DRG only, DRG with A431 and DRG with A431 
in the presence of cetuximab. A431 and DRG controls with cetuximab were not examined 
as the aim was to observe the effect of cetuximab on the migration and interaction of 
neurons and cancer cells in co-culture. Additionally, there was also a limited number of 
wells and space to contain microfluidic chambers. Cell population interactions were 
observed over a 48-hour period using live cell imaging (Zeiss Axiovert Live Cell Imager) 
with images taken every 5 minutes at 10x magnification.  
 
Quantification of cell area and migration distance was performed using ImageJ based off 
live images during the experiment. Three different locations were sampled and averaged 
within each experimental condition and tracked during the live imaging. Total area of 
growth and leading-edge distance of both cell populations was recorded at 0, 12, 24, 36 
and 48 hours and calculated using ImageJ area analysis and linear distance tools. This 
analysis was repeated for each experimental group. After live imaging, co-cultures were 
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fixed, and immunofluorescence was performed using anti-β-tubulin specific for neurons 
(TUJ1) and anti-EGFR (cetuximab) for cancer cells. 
 
6 Results 
6.1 EGFR expression in SCC cell lines  
 
Figure 6.1 Western blot analysis comparing anti-epidermal growth factor receptor 
antibodies. AB3, 31G7, SC120 and 111.6 antibodies were utilised at 1:4000 dilutions. 
A431 (high EGFR) and KJD (low EGFR) cell lysates were loaded and probes with anti-
EGFR antibodies (AB3, 31G7, SC120 or 111.6) utilised. Controls include a secondary anti-
HRP or anti β-tubulin controls.  
 
 
Four different antibodies to EGFR were obtained (31G7, SC120, AB3, 111.6) and Western 
blots were performed to validate and confirm antibody epitopes using A431 and KJD cell 
lines representing high and low EGFR expression respectively. A431 is a human 
epidermoid carcinoma derived from an 85 year old with significant EGFR overexpression 
(186). KJD cells are derived from normal keratinocytes transformed through SV40 virus 
(187). SCC15 and SCC9 cell lines are tongue derived SCC cell lines. Together they 
represent a range of relative levels of EGFR expression. To our knowledge there are no 
derived cell lines from cSCCHN with PNI or PNS. 
 
Western blots for EGFR are exemplified with high intensity bands detected for 31G7 and 
111.6 antibodies at molecular sizes above 150kDa and between 75-100kDa in the A431 
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cell line (Figure 6.1). EGFR is a 170kDa molecule. A weaker intensity band was detected 
between 150-250kDa in the KJD cell line. An absence of signal was detected to AB3 and 
SC120 antibodies in both cell lines (Figure 6.1). However, AB3 and SC120 are validated 
commercial antibodies known to bind to a native epitope and not be efficient for Western 
analysis (see below). A β-tubulin control validated the results and confirmed the presence 
of protein. 
 
Cell immunofluorescence was performed to confirm antibody efficacy and relative levels of 
EGFR expressions in the cell lines. Four different cell lines of epithelial carcinoma were 
obtained (A431, SCC15, SCC9, KJD) and immunofluorescently stained for EGFR (Figure 
6.2, Figure 6.3, Figure 6.4, Figure 6.5). Relative intensity of staining between antibodies 
was consistent across all cell lines, with 111.6 and SC120 generating the strongest 
intensity followed by AB3 and 31G7 consecutively. When comparing intensity between cell 
lines, A431 demonstrated the highest expression whilst KJD illustrated the least. The 
localisation of EGFR was as expected, with a plasma membrane and endocytic 
compartment distribution. Here the AB3 and SC120 antibodies, which did not give a strong 
signal by Western analysis, can be seen to bind in a distribution expected for EGFR and 
with a relative intensity in each cell line correlating with the laboratories enzyme-linked 
immunosorbent assay (ELISA) quantitative measurements of EGFR expression in each 
cell line, in agreement with the data on these antibodies indicating binding to a native 
epitope which is lost on denaturing of samples for Western. While 31G7 staining appears 
weak, the staining appears decreased as images were taken at the same laser power and 
settings which were low due to the high intensity of the SC120 staining. 
 
Overall, these experiments support our use of 31G7 as an EGFR antibody and confirm the 
A431 cell line in EGFR overexpression.  
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Figure 6.2 Cell immunofluorescence of A431 squamous cell carcinoma. Cells were 
fixed and stained with 4 different anti-epidermal growth factor receptor antibodies (31G7, 
SC120, AB3 and 111.6) and visualised with anti-mouse Alexa Fluor 647 secondary 
antibody (red). Cells were counterstained with DAPI (cyan). Scale bar represents 40μm. 
Images taken at x60 magnification using confocal microscopy. 
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Figure 6.3 Cell immunofluorescence of SCC15 squamous cell carcinoma. Cells were 
fixed and stained with 4 different anti-epidermal growth factor receptor antibodies (31G7, 
SC120, AB3 and 111.6) and visualised with anti-mouse Alexa Fluor 647 secondary 
antibody (red). Cells were counterstained with DAPI (cyan). Scale bar represents 40μm. 
Images taken at x60 magnification using confocal microscopy. 
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Figure 6.4 Cell immunofluorescence of SCC9 squamous cell carcinoma. Cells were 
fixed and stained with 4 different anti-epidermal growth factor receptor antibodies (31G7, 
SC120, AB3 and 111.6) and visualised with anti-mouse Alexa Fluor 647 secondary 
antibody (red). Cells were counterstained with DAPI (cyan). Scale bar represents 40μm. 
Images taken at x60 magnification using confocal microscopy. 
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Figure 6.5 Cell immunofluorescence of KJD squamous cell carcinoma. Cells were 
fixed and stained with 4 different anti-epidermal growth factor receptor antibodies (31G7, 
SC120, AB3 and 111.6) and visualised with anti-mouse Alexa Fluor 647 secondary 
antibody (red). Cells were counterstained with DAPI (cyan). Scale bar represents 40μm. 
Images taken at x60 magnification using confocal microscopy. 
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Table 6.1 Epidermal growth factor receptor staining index score by 
immunohistochemistry in primary cutaneous squamous cell carcinoma of the head 
and neck identified to later cause perineural spread 
Histopathological score – standardised histopathological scoring system (0 to 3). Intensity 
score – Hirsch intensity scoring system (1 to 4). Hirsch Index score calculated through 
multiplication of intensity score with percentage of tumour cells stained. An IHC score of ≥ 
2 and Index score ≥200 is required for epidermal growth factor receptor (EGFR) 
overexpression status. 
Identification 
Histopathological 
score 
Percentage of 
tumour cells 
stained (%) Intensity score Index score 
EGFR 
overexpression 
status 
J1 3 90 4 360 + 
J2 2 55 3 165 - 
J3 1 40 2 80 - 
J4 3 80 4 320 + 
J5 3 85 4 340 + 
J7 3 92.5 4 370 + 
J8 3 90 4 360 + 
J9 2 70 3 210 + 
J10 2 50 3 150 - 
J11 3 85 4 340 + 
J12 2 80 3 240 + 
J13 2 60 3 180 - 
J14 3 90 4 360 + 
J15 3 60 4 240 + 
J16 3 100 4 400 + 
J17 3 85 4 340 + 
J18 2 80 3 240 + 
J19 3 60 4 240 + 
J20 1 25 2 50 - 
J21 2 70 3 210 + 
J22 3 85 4 340 + 
J23 3 50 4 200 + 
J24 3 80 4 320 + 
J25 2 10 3 30 - 
J26 2 20 3 60 - 
J27 2 25 3 75 - 
J28 3 60 4 240 + 
J29 3 90 4 360 + 
J30 3 75 4 300 + 
J31 3 100 4 400 + 
J32 2 55 3 165 - 
J33 1 7.5 2 15 - 
J34 3 82.5 4 330 + 
J35 3 60 4 240 + 
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6.2 Primary cSCCHN overexpress EGFR prior to perineural spread 
EGFR overexpression is confirmed in large nerve PNS of cSCCHN but not in primary 
cSCCHN lesions. 34 specimens identified as primary cSCCHN leading to later PNS were 
obtained for IHC analysis against EGFR using the 31G7 antibody. Inclusion criteria 
necessitated a histopathological diagnosis of PNS from cSCCHN whilst patients were 
excluded if clinical symptoms and imaging of later PNS did not correlate with the location 
of the primary cSCCHN. Two independent pathologists performed EGFR IHC scoring 
using two parallel systems (histopathological scoring and the Hirsch intensity system) to 
minimize bias (Figure 6.6). In separate validation, 31G7 was shown to be the most 
effective antibody for IHC of EGFR and is used as a hospital pathology standard antibody 
in use for EGFR staining (66). The antibody is further validated by Western in Figure. 6.1 
and IF in Figures 6.2-5. 
 
Utilising the well-established histopathological scoring system, 91.18% (31/34) were 
scored as at least moderate staining intensity (≥2+) (Table 6.1). 70.58% (24/34) 
specimens were scored as EGFR overexpressing designated as an IHC score of at least 
moderate intensity and index score ≥200 (Figure 6.7). Of specimens deemed EGFR 
overexpressing, the average percentage of total tumour cells stained was 79.17% 
compared to 34.75% in non-EGFR overexpressing specimens (Table 6.1). When 
reviewing these specimens for PNI, 56% (19/34) specimens were discovered to have 
incidental PNI. 
 
These results support EGFR overexpressing tumours developing PNI as opposed to the 
process of PNI engendering EGFR overexpression. 
 
70 
 
 
Figure 6.6 Immunohistochemistry of EGFR in identified primary cSCCHN leading to 
PNS.  Examples of EGFR detection illustrating weak (1+), moderate (2+) and strong (3+) 
histopathological scoring. 31G7 primary antibody was used and staining performed with 
the Ventana staining system. Images are shown at 20x magnification with weak 1+ (A, B), 
moderate 2+ (C, D) and strong 3+ (E, F) staining. Scale bar at 50 μm. 
71 
 
 
 
  
Figure 6.7 Graphical representation of Hirsch Index score and histopathological 
scoring in primary cutaneous squamous cell carcinoma of the head and neck 
identified to later cause perineural spread. Left: Index score calculated through staining 
intensity and percentage of tumour cells stained (0-400). Right: Standardized 
histopathological scoring system of staining intensity. 
 
 
6.3 Checkpoint inhibitors in primary cSCCHN leading to later PNS 
Immunotherapy has steadily evolved with significant interest and investment in checkpoint 
inhibitors (168, 169). PD-L1 IHC staining was performed on 32 cSCCHN specimens 
identified as primary lesions of later PNS. 46.88% (15/32) had detectable staining of 
tumour cells but only 15.63% (5/32) had positive staining (TPS ≥25%) (Table 6.2). 84.38% 
(27/32) of the surrounding immune infiltrate in vicinity of tumour cells demonstrated PD-L1 
expression, however only 18.76% (6/32) had positive staining (IPS ≥25%) of surrounding 
immune cells in a 20x field expressing PD-L1 (Table 6.2).  SP263 antibody was used in a 
pre-dilute form approved and validated for hospital pathology (193). 
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Table 6.2 Programmed death-ligand 1 (PD-L1) staining of cutaneous squamous cell 
carcinoma of head and neck cancer identified as primary lesions of later perineural 
spread. 
Identification 
TPS scoring 
(%) 
Positive 
status (TPS 
≥25%) 
Proportion of 
immune cells 
stained (%) J1 10 - 10 
J3 0 - 60 
J4 0 - 2 
J5 0 - 2 
J7 2 - 2.5 
J8 20 - 5 
J9 0 - 10 
J10 0 - 5 
J11  0 - 5 
J12  0 - 0 
J13 25 + 2.5 
J14 0 - 10 
J15 0 - 10 
J16 10 - 60 
J17 90 + 60 
J18 0 - 5 
J19 0 - 50 
J20 70 + 20 
J21 5 - 5 
J22 0 - 10 
J23 2 - 40 
J24 10 - 10 
J25 2 - 20 
J26 90 + 5 
J27 0 - 0 
J28 70 + 20 
J29 0 - 0 
J31 0 - 20 
J32 2 - 30 
J33 0 - 10 
J34 20 - 0 
J35 0 - 0 
 
The Tumour Proportion Score (TPS) was used to score specimens based on percentage 
of total tumour cells stained for PD-L1. Positive status was taken if ≥25% of tumour cells 
were positive. Proportion of immune cells positive in the surrounding 20x field of view were 
also scored.  
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Table 6.3 Programmed cell death protein 1 (PD-1) staining of cutaneous squamous 
cell carcinoma of head and neck cancer identified as primary lesions of later 
perineural spread. 
Identification TPS scoring (%) 
Proportion of 
immune cells 
stained (%) 
J1 0 40 
J3 0 60 
J4 0 0 
J5 0 12.5 
J7 0 17.5 
J8 0 40 
J9 0 5 
J10 0 30 
J11  0 55 
J12 0 5 
J13 0 3.5 
J14 0 5 
J15 0 40 
J16 0 5 
J17 0 40 
J18 0 30 
J19 0 30 
J20 0 40 
J21 0 0 
J22 0 20 
J23 0 40 
J24 0 80 
J25 0 10 
J26 0 60 
J27 0 0 
J28 0 0 
J30 0 20 
J31 0 0 
J32 0 25 
J33 0 20 
J34 0 5 
J35 0 0 
 
The Tumour Proportion Score (TPS) was used to score specimens based on percentage 
of total tumour cells stained for PD-1. Proportion of immune cells positive in the 
surrounding 20x field of view were also scored. 
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Additionally, expression of PD-1 was examined via IHC on 32 specimens and tumour cells 
were uniformly negative against PD-1. When examining the surrounding immune infiltrate, 
81.25% (26/32) had positive staining of nearby immune cells with 43.75 % (14/32) of 
immune cells having a proportional of score ≥25% (Table 6.3). NAT105 antibody was 
obtained in a pre-dilute form previously approved and validated for hospital pathology 
staining (193). 
 
6.4 HER2 has no expression in primary cSCCHN of later PNS 
HER2 has shown promise in other epithelial malignancies such as breast cancer (66). IHC 
was performed for HER2 on 34 tumour specimens in line with inclusion criteria. 4B5 
antibody, utilised in hospital standard pathology testing and previously validated was 
employed (66). Analysis and scoring utilised the standard 4-point histopathological scoring 
requiring ≥10% of tumour cells to exhibit strong membranous staining to receive positive 
scoring (0 no staining, 1+minimal staining, 2+moderate staining, 3+ strong staining). 
Known HER2 positive controls were used to ensure validity of staining and reproducibility. 
HER2 staining was uniformly negative in primary cSCCHN identified as the cause of later 
PNS and may not be significant in perineural disease. 
 
6.5 Establishment of an in vivo pre-clinical model to investigate PNS of cSCCHN 
The investigation and IHC staining of FFPE specimens allow the discovery and 
confirmation of potential therapeutic targets for further experimentation in animal models. 
However, it cannot capture the technicality of complex disease processes such as PNI and 
PNS. The availability of an in-vivo model is an invaluable tool that models human disease 
and enables investigation into the efficacy of targeting potential drug targets. Hence, 
significant effort was made to set-up the first pre-clinical murine model of PNS of cSCCHN 
that allows study of disease progression without sacrificing the animal. 
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Figure 6.8 Schematic of A431-Luc2 tumour cell inoculation into whisker pad of NSG-
A2 mice. 10 NSG-A2 mice were inoculated with 20,000 (20 µL) A431-Luc2 cells via 
syringe injection into the right whisker pad after gaseous anaesthesia. Injections were 
performed bevel up at 20° to the horizontal to avoid direct seeding of the trigeminal branches 
(V2).   
 
10 NSG-A2 mice were chosen based on their immunodeficiency and inoculated with 
cancer cells at 6-8 weeks of age (194). 20,000 A431-Luc2 cells were injected into the right 
whisker pad of these mice (Figure 6.8). After inoculation, facial tumours became 
detectable at day 14. (Figure 6.9). An exponential growth pattern was exhibited when 
measuring tumour volume up to the target tumour volume of 0.2-0.5 cm3 was reached 
(Figure 6.9). Initial target tumour volume was 0.5 cm3, however due to the propensity and 
tendency for ulceration of these tumours, with the additional of clinical discomfort and 
distress to mice, the minimal acceptable target tumour volume for resection was changed 
to 0.2 cm3, aiming for surgical excision prior to tumour ulceration. The technical difficulty of 
en bloc resection of rapidly enlarging and ulcerating facial tumours for resection was 
another factor in operating at an earlier size and out of all mice, the maximal tumour size 
obtained was 0.49 cm3 prior to surgical resection.  
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6.5.1 Tumour inoculation and growth 
 
Figure 6.9 A431-Luc2 tumour growth and mice weight post subcutaneous 
inoculation of cells into whisker pads. 
 
Mice body weights post A431-Luc2 inoculation remained stable and gradually increased 
until 18 days post-inoculation when tumour volumes began reaching 0.2cm3 (Figure 6.9). 
Weight gains ceased in the context of increasing tumour size and began to fluctuate in the 
days prior to surgery (Figure 6.9). Post-operatively, weights dropped on average 8.03%. 
However, most mice regained weight post-operatively to pre-surgical values indicating the 
tolerance of mice to this level of surgery (Figure 6.9). 
 
6.5.2 Surgical procedure outcomes 
Once the decision was made for removal of facial tumours, when target volumes reached 
(0.2-0.5 cm3), surgical excision was performed on the 10 NSG-A2 mice. Mice were 
anaesthetised with intraperitoneal ketamine/xylazine combination allowing up to 60 
minutes of operating time. Skin flaps were raised towards the nose with care to avoid 
injury to the eyes, lacrimal system and mouth, as well as avoiding penetration into the 
paranasal sinuses. These A431-Luc2 tumours lacked a capsule and attempts were made 
to remove tumours en bloc. Adequate wound closure was achieved post-operatively 
through a combination of compression, electrical cauterisation and in all cases the skin 
layer was closed with Dermabond glue avoiding sealing of eyes or the snout (Figure 6.10). 
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Figure 6.10 Pre and post-surgical excision of A431-Luc2 whisker pad tumours of 
NSG-A2 mice.  The same NSG-A2 mouse seen (A) pre-operatively, (B) day 1 post-
operatively, and (C) day 10 post-operatively. 
 
Successful macroscopic surgical excision of the primary facial tumours was completed in 
90% (9/10) of mice. Failures of surgical technique resulted from the first mice in the 
context of sub-optimal anaesthesia with a subsequent shortened window to operate 
necessitating sacrifice of the mouse. The remaining procedures were completed 
successfully with macroscopic clearance of whisker pad tumours. One post-operative 
death secondary to an unknown cause was discovered day 1 post-operatively.  
 
6.5.3 Luciferase bioluminescence facilitates imaging of the A431-Luc2 cell line in 
vivo 
The ability of the IVIS spectrum optical imaging system to properly image A431-Luc2 bio 
luminesce was tested in vitro at different cell concentrations prior to use within in vivo 
imaging. Luminescence quantification can serve as a non-invasive measure of tumour 
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burden (195). In vitro quantification of A431-Luc2 cells illustrated increasing 
bioluminescence proportional to cell numbers (Figure 6.11). 
 
 
 
Figure 6.11 A431-Luc2 luciferase activity measured via IVIS spectrum optical 
imaging system. A - Bioluminescence assay in vitro performed after differing number of 
cells were seeded for 4 hours. Luciferin (150µg/mL) was added. B - Quantification of 
luminescence by total flux (photons/second).   
 
When 8 out of 10 mice were imaged 1 week post-operatively, all imaged mice illustrated 
bioluminescence at the surgical site (Figure 6.12). 4 mice illustrated an extension of 
luminescence caudally away from the surgical site. Two of these mice (M78, M7) 
demonstrated non-contiguous signal with bioluminescence in the region of the neck. 
However, these neck masses were unable to be analysed during histological 
decalcification of the head. No signal was detected over the skull. These results confirm 
the viability of luciferase bioluminescence live imaging. 
 
79 
 
 
Figure 6.12 Lateral and superior images of NSG-A2 mice 1-week post-surgery using 
IVIS Spectrum imaging  Magnification = Field of View (FOV): 4, image units: counts and 
Pixel Width/Height: 1. Luminescence settings were standardised for each mouse. 
 
6.5.4 Histological analysis demonstrates presence of PNI 
Whole mouse heads fixed and processed for histological examination were evaluated by a 
histopathologist for PNI or PNS. Each mouse head was sectioned at three locations at 90° 
to the course of the maxillary vision of the trigeminal nerve aiming to demonstrate the 
extent of PNS towards the skull base. No PNS, nor the spread of tumour cells away from 
the primary tumour were detected in any of these mouse heads (0/10). However, 20% 
(2/10) of all initial mice demonstrated microscopic PNI and up to 25% (2/8) excluding mice 
that did not complete post-surgical imaging (Figure 6.13).  
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Figure 6.13 Perineural invasion by A431-Luc2 cells in an NSG-A2 mouse   
Coronal sections of NSG-A2 mouse (A, B) and magnified x20 sections of perineural 
invasion (C, D) are seen. Cytokeratin (C) and S100 (D) special stains highlighting epithelial 
cancer cells and neuronal cells respectively. 
 
6.6 Optimisation of an in vitro non-clinical model to discover therapeutic targets 
Whilst the establishment of an in vivo model is crucial to assess efficacy of potential 
therapies of PNS, less expensive non-clinical models are also necessitated as a preceding 
step. In vitro models of perineural disease have been modelled successfully within 
pancreatic and prostate cancer, however minimal work has been put into PNI from 
cSCCHN (67). Therefore, multiple efforts at development of a non-clinical PNI model 
tailored specifically to cSCCHN allowing screening of potential therapeutic targets for later 
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in vivo study was performed. DRG were harvested from adult Balb/c mice between 3-4 
months and seeded into Xona chambers and also custom designed microfluidic devices 
(designed by Ms Priscila De Lima) based off commercial Xona chambers. Neurons could 
grow and establish with neurites extending into the microchannels of the scaffolding 
bridging the two compartments (Figure 5.2). Cell populations were separated by 450 μm 
prior to removal of scaffolding and interactions between these populations.  
 
 
 
Figure 6.14 Migration of A431 cells together visualised with brightfield and phase-
contrast microscopy. Neurons and A431 cells were visualised immediately (A) using the 
Olympus confocal microscope (FV3000) and 48 hours (B) after removal of Xona chamber 
scaffolding using the inverted epifluorescence (Olympus IX73) microscope. A431 cells in 
the absence of neurons were also visualised at 48 hours (C). Scale bars 100 µm (10X 
Magnification). 
 
DRG culture after 7 days demonstrated growth via the micro-channels and developing into 
the right side of the microfluidic chambers (Figure 6.14). A431 cells were seeded at a 
concentration of 2.5x10
6
cells/mL and the microfluidic scaffolding was removed allowing the 
co-culture interaction to be tracked via imaging with bright-field, phase-contrast, confocal 
microscopy and inverted epifluorescence (Figure 6.14). A431 cancer cells can be seen 
migrating towards DRG neurons post removal of chamber scaffolding despite loss of 
neurites when chambers were peeled. Plates where only A431 tumour cells were grown 
did not demonstrate the same migration pattern (Figure 6.14). 48 hours post seeding of 
A431 cancer cells cell immunofluorescence for TUJ1 and cytokeratin characterised and 
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confirmed the regrowth of neurites as well as the interaction between cell populations 
(Figure 6.15). 
 
Figure 6.15 Immunofluorescence of dorsal root ganglia and A431 co-culture. Images 
demonstrate immunofluorescence 9 days post initial seeding of neurons and 2 days post 
seeding of A431 cells. Neuronal (green) and cancer cells (red) were grown in two channels 
separated by microchannels facilitating neurite growth only. A431 cells were incubated for 
48 hours on the cancer side, post 7 days of neuronal culture alone to establish neurites. 
TUJ1 primary antibody was used to image neurons whilst cytokeratin was utilised for 
cancer cells. Secondary antibodies include goat anti-mouse Alexa Fluor 488 and anti-
rabbit Alexa Fluor 594 to image neurons and cancer cells respectively. Images were taken 
at 10x Magnification. Scale bars 150 µm. 
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6.6.1 EGFR blockade restricts migration towards DRG and invasiveness of A431-
Luc2 cells in vitro 
 
 
Figure 6.16 Quantification of dorsal root ganglia (DRG) and A431-Luc2 interaction in 
the presence of cetuximab.   Measurements of area and migration distance were made 
on ImageJ based on time-lapse microscopy of A431-Luc2 and DRG interaction in the 
presence of cetuximab. Cell area and migration distance of A431-Luc2 (A, B) and DRG (C, 
D) were plotted. Colour bars indicate A431 or DRG cells grown alone and in co-culture 
with or without cetuximab. 
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In vitro live imaging of A431-Luc2 and DRG interaction was performed with time lapse 
microscopy with phase-contrast images captured every 5 minutes. Cell surface area and 
net migration distance was calculated using ImageJ at five key time points (0, 12, 24, 36 
and 48 hours). Average cell areas and net migration distance were graphed (Figure 6.16).  
 
When examining the A431-Luc2 population, minimal changes in cell surface area and net 
migration was observed when co-cultured with DRG in the presence of cetuximab, 
whereas most growth was seen by A431-Luc2 cells alone. This is likely due to increased 
total area for cell expansion in the absence other cell populations competing for space.   
DRG growth was most significant when cultured with A431-Luc2 in the presence of 
cetuximab whilst DRG alone demonstrated the least growth comparing cell area and net 
migration (Figure 6.16). Logically, the slower growth of A431-Luc2 cells allow more 
potential for DRG cells to expand in a fixed container. 
 
Immunofluorescence was performed to confirm location and identities of cell populations 
using anti-β-tubulin specific for neurons (TUJ1) and anti-EGFR (cetuximab) (Figure 6.17). 
The leading edge of A431-Luc2 cells appeared to be maintained in the presence of A431-
Luc2 and DRG co-culture in the presence of cetuximab as opposed to a fragmented 
invasion front seen in the absence of cetuximab (Figure 6.17). A starting distance of 
450μm between the cell populations may not be large enough to properly demonstrate 
differences in invasion and growth as DRG and A431-Luc2 cells were in contact prior to 
completion of in vivo live imaging (Figure 6.17). As a pilot study without replicate results, 
no statistical analysis was performed. 
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Figure 6.17 Immunofluorescence of DRG neurons and A431-Luc2 co-culture after 
treatment with cetuximab. After treatment with 60µg/mL of cetuximab and time lapse 
microscopy for 48 hours, neurons (green) were stained with anti-β-tubulin specific for 
neurons (TUJ1) and A431-Luc2 cells (red) were stained with anti-EGFR (cetuximab). Goat 
anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 were used as secondary 
antibodies. Co-cultures of DRG+A431 and DRG+A431 treated with cetuximab were 
observed at (A) 10X and (B) 60X magnification. (C) A431-Luc2 only (control) at 10X and 
60X. (D) DRG neurons only (control) at 10X. (E) Secondary controls (60X) for both primary 
antibodies. Images were taken using the confocal (FV3000) microscope. Scale bars: 150 
µm (10X) and 50 µm (60X). 
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7 Discussion 
7.1 Potential therapeutic targets in treatment of PNS from cSCCHN  
7.1.1 Anti-EGFR antibody 31G7 is appropriate in investigation of EGFR 
overexpression 
EGFR and its associated downstream effects are well established in carcinogenesis (157). 
EGFR is overexpressed is in multiple malignancies including SCCHN, NSCLC, colorectal, 
breast, ovarian, pancreatic and prostate cancers with the expression of EGFR noted as an 
important biomarker for response to anti-EGFR therapy and survival (196). Logically, 
EGFR IHC has emerged as a tool to select potential responders to monoclonal antibody 
treatment such as use of cetuximab against colorectal cancer, as well as against NSCLC 
(197).  
 
With increasing numbers of commercially available EGFR-antibodies, discrepancies may 
arise in staining patterns of different antibodies against EGFR (198). Although nonspecific 
binding can be reduced via use of monoclonal versus polyclonal antibodies, target 
epitopes may include short sequences on amino acids that may exist on other proteins 
(199). Therefore, appropriate validation of antibody is crucial. Four different commercially 
available anti-EGFR antibodies were compared by Western blot analysis and cell 
immunofluorescence to validate antibody epitopes and suitability for further 
experimentation (Figure 6.1). The antibodies had been previously validated in the 
laboratory for use in IHC (66). Although AB3 and SC120 antibodies illustrated no 
detectable bands by Western analysis, they are mouse monoclonal antibodies utilised 
commonly in research applications including immunoprecipitation (200). The absence of 
detectable bands by Western analysis suggests their target epitope exists in the native but 
not denatured conformation of the EGFR protein. Both 31G7 and 111.6 EGFR clonal 
antibodies demonstrated detection of an identical distribution of bands on Western blot at 
the published and expected size of denatured EGFR.  
 
Immunofluorescence against four different cell lines was performed to confirm relative 
levels of EGFR expression prior to later use in DRG experimentation. 111.6 and SC120 
anti-EGFR clones generated the most significant intensity of signal, followed by AB3 and 
31G7 respectively confirming the presence of the natural epitope (Figure 6.2, Figure 6.3, 
Figure 6.4, Figure 6.5). Although the fluorescence intensity of 31G7 was the least out of 
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the four anti-EGFR antibodies, this is likely highlighted by optimisation of microscopy 
settings to maximise adequate visualisation of all cell lines without oversaturation of any 
cell line, especially in imaging of A431 cells with high EGFR expression. Additionally, 
31G7 is an established pathology validated antibody used in IHC staining of colorectal and 
NSCLC specimens (196, 198). Additionally previous IHC validation in the laboratory 
showed that 31G7 was the best antibody for use on FFPE sections (66). For these 
reasons, 31G7 was chosen for all further EGFR IHC detection and Western, while SC120 
works well for IF.  
 
7.1.2 cSCCHN overexpress EGFR highlighting its potential role in perineural 
disease  
 
EGFR overexpression is reported in one third of epithelial malignancies including lung, 
ovarian, breast, colorectal, prostate and bladder cancers (201). Recently our laboratory 
has demonstrated EGFR overexpression in 90% of cSCCHN with PNS similar to that of 
mucosal HNSCC (202). To our knowledge, EGFR expression in index cSCCHN lesions 
identified with eventual PNS has not yet been examined. 
 
In our series of specimens, EGFR overexpression was demonstrated in 70.58% (24/34) 
and at least moderate intensity of EGFR expression in 91.18% (31/34) of specimens 
(Table 6.1). Interestingly this appears to be significantly higher than reported in primary 
cSCC (155). Although limited numbers and varying EGFR analysis criteria were employed 
in previous experiments, EGFR overexpression has been demonstrated in approximately 
45% of cSCC and associated with poorer prognostic implications (11, 155, 156). Canueto 
et al. (2016) illustrated 35% (33/94) EGFR overexpression in resected cSCC as well as 
detectable expression in 90.4% of specimens (155). Other studies by Ch’ng et al. (2008) 
and Sweeny et al. (2012) found a similar rate with 36% (9/52) and 56% (28/50) 
overexpression in primary cSCC respectively. When factoring nodal metastases Ch’ng et 
al. (2008) and Sweeny et al (2012) demonstrated overexpression in 47% (7/15) and 58% 
(7/12) of specimens for EGFR (156, 157). 
 
EGFR overexpression is correlated with aggressive disease with a trend towards 
increasing invasiveness with increasing EGFR expression. However, there is a paucity of 
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evidence when examining recurrent metastatic cSCC and their primary lesions. In a case 
series of 13 recurrent metastatic SCC lesions, strong plasma membrane staining was 
elicited in all (13/13) metastatic lesions, a study which also  utilised our chosen EGFR 
antibody (31G7) (203) . Another study comparing primary cSCC and their metastatic 
lesions cited overexpression in 80% (4/5) of metastatic lesions with lower intensity of 
primary tumours (204). It is difficult to make strong conclusions secondary to very limited 
numbers and a lack of standardization in EGFR IHC and interpretation. We know that PNS 
is a mode of tumour metastasis whereby cells infiltrate nerves. Similar to EGFR 
overexpression, PNI and PNS also portends more aggressive disease with significantly 
worse outcomes, correlating with invasiveness and high recurrence rates (37). The 
previous finding of 90% EGFR overexpression in PNS of cSCCHN suggested the 
potentiation of perineural spread by EGFR although an elucidation of whether a subset of 
these tumours undergo PNS or the process of PNS generates EGFR overexpressing 
tumours has not been discussed (66). Our finding of 70.58% (24/34) EGFR 
overexpression support that the subset of cSCCHN with high EGFR overexpression are 
more likely to undergo tumour metastasis by way of perineural spread.   
 
Current available treatment options for metastatic or recurrent SCCHN are limited and are 
offered a combination of salvage surgery, radiotherapy and supportive cares (205). EGFR 
is highly expressed in SCCHN and portends a poor prognosis (157). Together with 
radiotherapy, cetuximab significantly improves survival compared to radiotherapy alone for 
treatment of recurrent or metastatic SCCHN (26% risk reduction of death, 32% risk 
reduction of locoregional recurrence) (206). Despite EGFR overexpression in 
approximately 45% of cSCC and greater than 90% of mucosal SCCHN, monotherapy 
targeting EGFR or in combination with chemotherapy demonstrated a maximum response 
rate of 13% in SCCHN who failed first line platinum-based therapy (157, 205). This 
suggests a lack of relationship between IHC immunoreactivity to EGFR, and treatment 
response to EGFR-targeted therapies (207, 208). NSCLC also has an overexpression of 
EGFR up to 89% of cases (209). Similarly, there is non-conclusive evidence suggesting its 
association with treatment response to TKIs (210). Approximately 75% of colorectal cancer 
patients express EGFR but objective responses to cetuximab are independent of EGFR 
status resulting in the removal of routine EGFR analysis in the National Comprehensive 
Cancer Network recommendations for metastatic colorectal cancer (211, 212). 
Interestingly Kras is a biomarker associated with decreased responses to anti-EGFR 
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therapies and is theorised that Kras mutations independently activate the downstream 
pathways of EGFR including RAS/MAPK signalling (213). Kras mutation status and not 
EGFR expression dictates cetuximab use in metastatic colorectal cancer(213, 214).  
 
Previously EGFR analysis of cSCC in the literature each used a different scoring system. 
Canueto et al. (2017) and Ch’ng et al. (2008) both utilised independent observers to 
stratify specimens into weak, moderate or strong staining accepting EGFR overexpression 
with only strong staining accepted as overexpression, although no minimal staining 
proportion was required (155, 156). Maubec et al. (2005) and Shimizu et al. (2001) used a 
similar staining intensity grading but did clarify their threshold for EGFR overexpression 
(203, 204). Within NSCLC and colorectal cancer, grading of EGFR expression was based 
on a similar weak, moderate and strong intensity score although proportion of tumour 
scores were factored in with Parra et al. (2004) requiring greater than 20% staining of total 
tumour cells as a threshold for EGFR overexpression (215-220). More recently an index 
score or an “H score” was employed by Aviles-Salas et al. (2017) for NSCLC combining 
both intensity and percentage of tumour stained into an index score requiring a score 
greater than 200 for high EGFR overexpression (221). Due to an absence of a 
standardised scoring system for cSCC, analysis of EGFR overexpression in our samples 
combined two clinically established scoring systems; the widely utilised 4-point intensity 
histopathological scoring system and the Hirsch index scoring system (188). This was 
done to increase confidence correctly scoring EGFR overexpression in the context of 
variable EGFR staining analysis (222). 
 
Perineural invasion and spread is a unique form of tumour metastasis and this process 
relies on the intrinsic mechanisms of cell migration and invasive growth (12). Accumulating 
evidence suggests EGFR expression plays a part in metastasis. Signalling via tyrosine 
kinase receptors, EGFR regulates downstream cell proliferation and survival, and hence 
abnormalities or overexpression may lead to tumour development and invasion (223). 
However, other downstream effects such as enhanced tumour migration, invasion, and 
angiogenesis may be more significant to patient prognosis in terms of metastasis. The 
mechanisms of EGFR in migration, invasion and metastasis have been reviewed (224). 
Whilst clinical and laboratory research of EGFR in metastatic disease have been reviewed 
in HNSCC, glioblastoma, penile SCC and NSCLC, the role of EGFR in metastasis of 
cSCC is poorly understood. Using oral SCC cell lines in vitro, Ohnishi et al. (2017) have 
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demonstrated the inhibition of oral SCC cell migration with the administration of cetuximab 
(223, 225). This further promotes the notion of EGFR as a cellular motility and migration 
molecule.  EGFR overexpression SCC may therefore have a predilection for invasion due 
to its developmental capability for growth and invasion. Shimizu et al. (2001) in an analysis 
of 5 primary cSCC and 5 metastatic lesions demonstrated EGFR overexpression in 4 out 
of 5 cSCC tumours (both primary and metastatic lesions). The EGFR expression in the 
metastases were diffusely and strongly positive compared to weakly positive in the primary 
tumours with genomic hybridization leading to the hypothesis that EGFR is required to 
confer metastatic potential (204). Our own observations in actinic keratoses, Bowen’s 
disease and cSCC highlight that EGFR can become polarised to the leading edge of the 
basal layer of tumours (189). Given that cellular cytokinetic response to EGFR signalling 
can lead to migration and metastasis, the potential for invasion in polarised cells is high 
and it will be of interest analysing the potential of an actinic keratosis with high polarisation 
to develop into an SCC. 
  
The role of EGFR in skin repair and inflammation has been reviewed (146). EGFR is 
required for physiological development of epithelial tissue as well as neural innervation to 
the skin with EGFR null mice demonstrating significant multi-organ abnormalities (130, 
131, 134, 135). However, in the context of increasing clinical use, the adverse side effects 
of anti-EGFR therapy have made the role of EGFR in skin repair and inflammation a focus 
of research. Interestingly, the dermatological side effects of anti-EGFR therapy have 
shown to correlate with improved clinical outcome, but the clinical, social and 
psychological effects have led to dose reductions and limitations on use of the therapy 
(226), Two different authors, Mascia et al. (2013) and Lichtenberger et al. (2013) have 
shown that EGFR inhibition results in recruitment of immune cells secondary to chemokine 
secretion by keratinocytes (227, 228). Secondly, EGFR activation is required for secretion 
of anti-microbial proteins used in skin barrier defence (228). Hence patients receiving anti-
EGFR therapy are at increased risk of developing skin infections. A significant portion of 
anti-tumour therapy attributed to EGFR inhibition has been theorised to be mediated 
indirectly via the immune system (229). Thus, new therapies designed to reduce 
dermatological reactions must not eliminate or dampen the anti-tumour effects.  
 
There are some limitations in the conclusions drawn from our series of primary cSCC 
identified to later cause PNS. Approximately one quarter of PNS of cSCCHN have no 
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identifiable primary lesion and it can be difficult to identify primaries in patients with a 
significant history of chronic sun damaged skin (52). Through tumour immune surveillance 
it is assumed that these primaries are eliminated before they are detected although PNI 
may have already occurred (230). From previous research published by our laboratory, 
despite the presence of CD4 and CD8 T cells within the perineural tumour mass, tumour 
growth and invasion continues (182). Therefore, immunosuppression mechanisms through 
employment of NKT cells and checkpoint inhibitory molecules such as PD-1 by tumour 
cells may play a role causing immune cell dysfunction (173, 231).   
 
However, through our stringent inclusion criteria, and exclusion of dubious lesions, we are 
confident in the identification of the index lesions analysed as causing later PNS in 
cSCCHN. Other limitations inherent within IHC and its interpretation were considered 
through use of two independent pathologists blinded to our study hypotheses to minimise 
bias and maximise reproducibility. Finally, limitations on the breadth of patient data 
collected prevented further clinical extrapolations. 
 
Currently, EGFR is not regarded as a prognostic indicator or biomarker in cSCC, and 
cSCCHN with or without PNI. Whilst associated with metastatic disease, in fully formed 
tumours there is no clinical correlation of EGFR with tumour growth or patient outcome, 
although recent data has illustrated that receptor trafficking and polarisation can influence 
the metastatic potential (189, 224). However, in combination with previous findings from 
our laboratory, our data supports EGFR as a driver of PNS in cSCCHN rather than the 
process of perineural invasion and spread engendering EGFR overexpression (66). This 
highlights EGFR as a potential prognostic factor to examine in primary cSCC in 
combination with other high risk features such as mid-face location, poor differentiation 
and tumour size (40). If tested, post-resection protocols of primary cSCC with EGFR 
overexpression can guide follow-up with such patients registered as high risk for future 
perineural disease and institution of closer follow-up with planned or low thresholds for MR 
neurography. Thus, avoiding the devastating scenario of late presentations of cSCC with 
PNS necessitating radical and morbid surgery with poorer outcomes 
 
7.1.3 HER2 likely has no role in PNI of cSCCHN 
PNI is likely not a homogenous process with heterogeneity contributing to resistance and 
poor treatment response (66). Known pathways of tumour resistance include alternative 
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signalling pathways (154). Logically, multi-targeting of ErbB family receptors can mitigate 
this resistance, with EGFR and HER2 pathway blockade demonstrated to synergistically 
inhibit invasiveness and proliferation in vitro (232). Additionally, lapatinib targeting EGFR 
and HER2 as well as multi-ErbB treatment regimens utilising 6 antibodies have also shown 
promise in inhibition of cancer growth (233). 
 
HER2 is a known heterodimerisation partner for other ErbB family receptors including 
EGFR and its potential in primary cSCC for perineural invasion or spread has not been 
examined. There was no expression of HER2 in our series of primary cSCCHN specimens 
associated with later PNS supported by an established and reproducible IHC protocol. Our 
findings validate that of the literature with HNSCC demonstrated only 2% (2/94) of oral 
SCCs and 5% (2/42) of laryngeal SCCs overexpressing HER2 (234). Supported by an 
absence in PNS of cSCCHN specimens also, we deduce HER2 plays no role in perineural 
spread of cSCCHN (66). 
 
7.1.4 PD-1 and PD-L1 are potential therapeutic targets for treatment of PNS in 
cSCCHN 
The role of the immune system is established in pathogenesis of cSCC. This is evident in 
immunosuppressed patients with increased risk of NMSC and elevated recurrence and 
metastases risk. Immune infiltrates are known to interact in cSCC with one study 
illustrating 65% (n=83) of primary cSCC and 90% of metastases demonstrating their 
presence (235). This is additionally demonstrated by adequate responses of pre-
cancerous skin lesions to topical immunotherapy as well as a 50% response rate  
response to cemiplimab (13/26) (168, 236). Therefore, checkpoint inhibitors of the immune 
system may have a role in treatment of PNS from cSCC. 
 
In our series of primary cSCCHN identified to cause later PNS, detection of PD-L1 was 
seen in 46.88% with only 15.63% scored as positive (TPS ≥25%) (Table 6.2). When TILs 
were examined, 84.38% (27/32) demonstrated detection of PD-L1, but only 18.76% were 
scored as positive (TPS ≥25%). PD-1 staining performed on 32 specimens were uniformly 
negative in tumour cells. 50% (26/32) had positive staining of nearby immune cells with 
43.75% scoring positive (TPS≥25%). One study investigating PD-L1 expression defined 
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positivity as ≥5% of tumour cells and demonstrated 26% of primary cSCC positive for PD-
L1 and demonstrated higher rates of PD-L1 associating with nodal metastases (237).  
 
PD-L1 expression has been proposed as a predictive biomarker with high expression of 
PD-L1 indicating better responses (238). Most research to date focuses on PD-L1 
expression over PD-1, partly due to PD-L1 antibodies being superior in reverting PD-1 
signalling (239). Emerging data suggests PD-L1 overexpression in tumours have improved 
outcomes with checkpoint inhibitor therapy, although this is complicated by significant 
responses by patients with PD-L1 negative tumours (240, 241). PD-L1 alone may be 
inadequate in stratifying treatment options with evidence for PD-L1 is an inducible factor 
and hence will have altered expression status based on environmental stresses and 
immune status. Results of PD-L1 expression assays are affected by a variety of factors 
including size of specimen, biopsy location and components of tumour (242). Concerns 
also are raised over the effects of previous chemotherapy or radiotherapy in the induction 
of PD-L1 expression. Previous analysis of PD-L1 expression have utilised a plethora of 
PD-L1 antibody clones, with each antibody employing a different cut-off for PD-L1 
positivity. Four PD-L1 IHC assays have been FDA approved including the antibody used in 
our experiment (SP263). Each antibody has its own assay and there is no standardization 
between them. SP263 is employed in the assay for durvalumab, and validated and 
approved for NSCLC and HNSCC via clinical trials (235). Interestingly, at least two studies 
have compared 3 of these antibodies (SP263, Dako 22C3 and Dako 28-8) with a high 
concordance or overall agreement of greater than 90% between assays in NSCLC 
patients (242). It is therefore not surprising, that there is currently no universally accepted 
threshold to define PD-L1 positivity. Complicating matters, significant response rates to 
checkpoint therapy also have been reported in the absence of PD-L1 detection. 
 
In NSCLC, PD-L1 positivity with a cut-off of ≥1% has been shown to correlate with 
improved survival with a meta-analysis illustrating significantly higher overall response rate 
(ORR) (OR: 2.44; 95% CI 1.61-3.68, n=914) in PD-L1 positive tumours over negative (241, 
243). The issues of testing immune over tumour cells is also dubious. Herbst et al. (2014) 
showed PD-L1 expression on TILs predicted response better than on tumour cells 
suggesting better patient selection can be facilitated through screening of both TILs and 
tumour cells for PD-L1 expression (244). However this raises flaws with inter and intra-
94 
 
observer bias interpreting TILs as innate difficulty lies in discriminating oncogenic versus 
inflammatory lymphocyte invasion (245).  
 
Recent studies have suggested combination therapy with anti-PD-1/PD-L1 therapies and 
anti-EGFR therapies (96). Initially examined in NSCLC with EGFR mutations, anti-EGFR 
therapy was suggested to modulate antitumour immune response by upregulation of PD-
L1 (96). When combined with anti-PD-L1 treatment, anti-EGFR therapy was demonstrated 
to increase efficacy of trastuzumab in mice (98). Individual cases such as an invasive 
cSCC in the pre-auricular space demonstrated remission after treatment with combination 
cetuximab and nivolumab in 6 months (72).  
 
PD-L1 expression is confirmed in mucosal SCC of oropharynx, oral cavity, larynx and 
nasopharynx as well as in cutaneous cancers such as Merkel cell carcinoma and 
melanoma (166). Checkpoint inhibitors are promising field of novel cancer therapy, with 
success in recent trials of metastatic cSCCHN (28, 29). Our data illustrates a potential role 
for PD-1/PD-L1 inhibition on cSCCHN with PNI or PNS requiring proper elucidation with 
future work in animal models. 
 
7.2 Optimisation of an in vivo model to study PNS  
Previous models of perineural spread include orthotopic models whereby direct injection 
into target organs successfully creating a PNI model (69, 70). However, through this 
iatrogenic insertion, numerous steps of pathogenesis are skipped creating a likely different 
disease phenotype to that in humans. Reliable models such as the pancreatic in vivo 
carcinogenesis-induced model accurately mimics human disease whilst maintaining 
tumour-nerve interactions proving a valuable resource for pancreatic cancer neurotropism 
investigation (72). Unfortunately, the pathophysiology of cSCC with PNS has not been 
properly elucidated and there is no known equivalent genetic mutation with significant 
penetrance similar to Kras in pancreatic adenocarcinoma (72). To better emulate a 
physiological model, we optimised the first in vivo model of PNS in cSCC by our 
colleagues at QIMR allowing imaging of disease progression without the need to cull the 
animal (73).  
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The whisker pad of mice is a highly innervated region corresponding to physiological 
functions of mice, thus allowing us to mimic human pathogenesis of cSCCHN as the V2 
branch of the trigeminal nerve is most commonly involved in perineural spread (33). Our 
surgical technique of subcutaneous injection also avoids direct injection into nerves, and 
the best option available due to the technical difficulty of epidermal injection. With the 
introduction of cancer cells into the subcutaneous space, we have permitted the natural 
pathogenesis of disease progression minimising disruption to the tumour-nerve 
microenvironment. 
 
The ideal number of tumour cells (20,000) was already investigated by our colleagues to 
facilitate reliable growth with detection by day 14 and maximum size by day 32 (73). 
Similarly, our experiment discovered facial tumours by day 14 with the last surgical 
resection performed on day 25. Knowing the significance of the immune system in 
prevention of skin cancer, it is not surprising immunodeficient NSG-A2 developed tumours 
at a faster rate (172). We found that 20% of mice developed PNI confirming the potential 
of developing perineural disease in these mice. Although seemingly low, this also mimics 
human PNI rates of less than 14% from cSCC (33). Diagnosis of PNS occurs months to 
years after the initial lesion is removed in humans and therefore, the development of the 
tumour too rapid leading to animal euthanasia before PNS occurred. 
 
Use of bioluminescence has also been confirmed to function adequately in imaging A431 
cancer cells in living mice (Figure 6.12). This has a significant advantage over other 
models in the capability to keep the mice alive during experimentation and allowing real-
time assessment of tumour response without the need to sacrifice the animal. Treatment 
parameters such as efficacy, duration and resistance to tested therapies can be detected 
and addressed efficiently whilst minimising animal experimentation demonstrating a 
significant advantage over the previous iteration (73). Additionally, the option to confirm 
treatment response on histopathological analysis is not eliminated. Further optimisation is 
also required over optimisation of image clarity (Figure 6.11). Bioluminescence has 
traditionally produced high-resolution imaging at the cellular level (246). However, it is not 
currently possible to image single cells in vivo as we are interested in the progression of 
the tumour bulk along peripheral nerves through skin and subcutaneous tissue. 
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During surgery, the morbidity of tumour location caused both potential distress to mice but 
also increased technical difficulty in en bloc tumour extraction (Figure 6.12). Growth of 
tumour within the whisker pads can cause paraesthesia and interference with 
environmental interaction due to loss of motor and sensory stimuli through this important 
sensory organ (247). The trigeminal nerve has three divisions (V1 ophthalmic, V2 maxillary 
and V3 mandibular), and although V2 was utilised in this experiment, there is merit in 
utilisation of the ophthalmic branch for future studies. Injection of tumours into the 
forehead or scalp avoids the sensory region of the snout potentially reducing morbidity and 
allowing a simpler surgical excision. Future pilot studies may benefit from investigating the 
efficacy of V1 as a target nerve for future PNS studies. 
 
Molecular mechanisms of PNS from cSCCHN are poorly understood as seen in the 
literature (12). Our model of perineural disease offers a novel method of live imaging with 
the ability to monitor real time efficacy of therapeutic options. This also eliminates the need 
for early animal sacrifice to assess outcomes, although the advantage of histopathological 
analysis remains accessible at the end of the experiment.  
 
7.3 An in vitro model for screening potential therapeutic drugs against PNS  
Not all potential therapeutic targets can be immediately examined utilising in vivo models 
due to their expense and technical difficulty. Simpler and cheaper in vitro systems, 
although without the capability of modelling tumour-nerve microenvironments, allow the 
establishment of a rigorously controlled environment with minimal variables relative to in 
vivo systems. DRG models have been well employed in prostate cancer since Ayala et al. 
(2001) first illustrated symbiotic advantages in co-culture of DRG with prostate cancer cells 
(67). More recently the adaptation of microfluidic devices allows spatial and temporal 
separation of cell populations through their compartmentalisation facilitating screening of 
potential therapeutic targets. 
 
Many conditions can be tested using multiple DRG harvested from a single mouse 
allowing numerous conditions to be tested simultaneously maximising use of resources. 
During growth of neurites, live imaging allows monitoring and time-lapse video recording to 
assess real-time efficacy of treatment conditions (Figure 6.14). The option for 
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histopathological analysis upon conclusion of the experiment is extremely advantageous 
and allows confirmation of cell types and extent of growth (Figure 6.15). 
 
However, there are limitations to the use of DRG in this in vitro model. Employment of 
DRG in the study of PNS is a technically challenging method with critical steps in the 
extraction and dissection of microscopic DRG from mice spinal columns requiring a 
significant investment to learn the technique. Microfluidic chamber design was based on 
Lei et al. (2016) to replicate neurite growth and establishment. Neurites are extremely 
delicate with potential for neurite loss with excess handling as removal of surrounding 
scaffolding can destroy neurite networks (Figure 6.15). This was a major drawback that 
may have been in part due to the narrow diameter of the microchannels preventing 
adequate neurite establishment. This prevented the collection of more quantitative 
replicated data. Additionally, although neurites are used as surrogates for large nerve 
invasion, the clinical significance of neurite growth and interaction with cancer cells have 
not yet been observed in clinical practice and may not correlate. Finally, due to the 
constraints of Xona chamber design, cell interactions can only be observed for 48 hours or 
less due to distance travelled between the cell populations (Figure 6.14). This is in contrast 
to human PNS requiring months to years to develop (33).  
 
A pilot study was performed utilising in vitro live imaging of A431-Luc2 and DRG cells with 
time lapse microscopy in the presence of cetuximab (Figure 6.16). A431 cell growth was 
limited in the presence of cetuximab compared to without although DRG growth appeared 
greatest together with cetuximab. Due to the fixed volume of the experimental conditions, 
A431-Luc2 cells would limit the volume for DRG expansion. This highlights a limitation in 
the experimental design with regards to separation distance between the cell populations 
at commencement of the experiment as DRG and A431-Luc2 cells can contact prior to 
completion of in vivo imaging (Figure 6.17). 
 
Future improvements to this model require a larger distance of separation between cell 
populations to allow accurate observation of cell interactions. Further replicates are 
required for proper statistical analyses. Further investigation into DRG culture and harvest 
techniques may be useful in improving DRG survival and yield to decrease the number of 
animals required. Overall, this adaptation of microfluidic devices allows both spatial and 
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temporal control facilitating cheap screening of potential therapeutic targets for use in in 
vivo modelling.  
 
8 Conclusion 
PNI is an accepted risk factor for poorer prognosis in cutaneous squamous cell carcinoma 
of the head and neck (cSCCHN) with increased locoregional recurrence, more aggressive 
disease and metastasis (61). PNI and PNS are poorly understood forms of tumour 
metastasis with no prognostic markers nor effective therapies established (102). These 
findings have significant implications for management of PNI and PNS from cSCCHN. 
 
Unsurprisingly, anti-EGFR therapies have emerged to treat epithelial malignancies due to 
EGFR overexpression correlating with increased invasiveness and its potential role in 
metastasis. With analysis of index cSCCHN lesions prior to the development of PNS, 
EGFR overexpression was demonstrated in 70.58% of specimens (24/34) highlighting its 
potential role in cSCCHN. Currently, EGFR is seen as a prognostic indicator or biomarker 
in cSCC, and cSCCHN with or without PNI. Whilst associated with metastatic disease, in 
fully formed tumours there is no clinical correlation of EGFR with patient outcomes, 
although recent data has illustrated that receptor trafficking and polarisation can influence 
the metastatic potential (189, 224). In combination with previous findings from our 
laboratory, our data supports EGFR as a driver of PNS in cSCCHN rather than the 
process of perineural invasion and spread engendering EGFR overexpression (66). Once 
further elucidated, new staining protocols and follow-up guidelines should be instituted for 
EGFR overexpressing cSCC as high risk for future perineural disease and institution of 
closer follow-up with planned or low thresholds for MR neurography.  
 
Further elucidation of PNI mechanisms can be properly investigated with the help of in vivo 
and in vitro models allowing further light to be shed upon the mechanisms of EGFR and 
other potential molecules. A promising avenue of future research involves proteomic 
analysis of PNI using our fresh frozen tissue and may discern molecular differences 
associated with perineural disease. Ultimately, it is our aim to improve patient outcomes in 
not only PNS of cSCCHN, but other neurotropic carcinomas. 
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1. Project Title 
 
Studying the factors involved in the perineural spread of Head and Neck 
Malignancy 
 
 
2. Principal Investigators and Co-
Investigators Principal 
Investigators 
 
Name: Professor Benedict Panizza MBBS, MBA, MAICD, FRACS 
Position: Director, Department of Otolaryngology, Head and Neck Surgery 
 Co-Director, Queensland Skull Base Unit 
Address: Princess Alexandra Hospital 
Telephone: 07 3839 9112 (private rooms) 
Email: ben@panizza.com.au 
Name: Professor Peter Parsons PhD 
Position: Principal Research Fellow 
Address: Queensland Institute of Medical Research 
Telephone: 07 3362 0316   
Fax: 07 3845 3508   
Email:  Peter.Parsons@qimrberghofer.edu.au   
Co-Investigators 
Name: Dr Timothy Warren 
Position: Principal House Officer / Registrar ENT 
Address: Queensland Health 
Telephone: 07 3176 6899   
Email: tawarren1@me.com 
Name: Dr Glen Boyle PhD 
Position: Research Officer 
Address: Queensland Institute of Medical Research 
Telephone: 07 3362 0319   
Fax: 07 3845 3508   
Email: Glen.Boyle@qimrberghofer.edu.au 
Name: Dr Ian Brown 
Position: Visiting Pathologist 
Address: Envoi Pathology & The Royal Brisbane and Women’s Hospital 
Telephone: 07 3377 8666   
Email: IanBrown@envoi.com.au 
Name: Dr Duncan Lambie 
Position: Pathologist / Senior Medical Officer 
Address: Department of Anatomical Pathology, Princess Alexandra Hospital  
Telephone: 07 3176 6781   
Email: Duncan.Lambie@health.qld.gov.au    
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Name: Dr Gary Quagliotto 
Position: Pathologist 
Address: Sullivan Nicolaides Pathology 
Telephone: 07 3377 8473    
Email: gary_quagliotto@snp.com.au 
Name: Professor Ian Frazer 
Position: Director 
Address: Translational Research Institute 
Telephone: 07 3443 8042    
Email: I.Frazer@uq.edu.au 
Name: Dr Graham Leggatt 
Position: Senior Lecturer/Senior Research Fellow 
Address: University of Queensland Diamantina Institute, QIMR 
Telephone: 07 34436961    
Email: G.Leggatt@uq.edu.au 
Name: Professor David Whiteman 
Position: Clinical Epidemiologist 
Address: Queensland Institute of Medical Research 
Telephone: 07 3362 0279    
Email: David.Whiteman@qimrberghofer.edu.au    
Name: Professor Sandro Porceddu 
Position: Radiation Oncologist 
Address: Princess Alexandra Hospital 
Telephone: 07 3176 7111     
Email: Sandro.Porceddu@health.qld.gov.au    
 
Name: Dr James Bowman 
Position: Otolaryngologist 
Address: Princess Alexandra Hospital 
Telephone 07 3176 5266    
Email: jamesbowman@me.com    
 
Name: Dr Caroline Cooper 
Position: Staff Specialist Pathologist 
Address: Pathology Queensland- Princess Alexandra Hospital 
Telephone: 3176 6781    
Email: Caroline.Cooper@health.qld.gov.au    
Name: Professor Phillip Robinson 
Position: Head, Cell Signalling Unit 
Address: (ProCan(TM): The ACRF International Centre for the Proteome of Human 
 Cancer) 
 Children’s Medical Research Institute 
Telephone: 02 8865 2800    
Email: PRobinson@cmri.org.au  
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Name: Dr Johnson Huang 
Position: Principle House Officer 
Address: Princess Alexandra Hospital 
Telephone 07 3176 3219  
Email: johnson.da.huang@gmail.com 
Name: Dr Fiona Simpson 
Position: Research Fellow 
Address: Translational Research Institute 
Telephone 07 3443 6930  
Email: f.simpson@uq.edu.au  
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3. Location 
 
The Princess Alexandra Hospital  
Queensland Institute of Medical Research 
Diamantina Research Institute 
Translational Research Institute  
ProCan(TM): The ACRF International Centre for the Proteome of Human Cancer, 
Children’s Medical Research Institute 
 
 
 
4. Rationale and Objectives 
 
Malignancies of the head and neck are extremely common, particularly in Queensland. 
Rates of perineural invasion by malignancies vary and range from 0.18 – 10% in basal 
cell carcinomas and 2.5 – 14% in squamous cell carcinomas1. All malignancies with 
perineural involvement are associated with a poorer prognosis. Within the head and neck, 
perineural spread can readily involve the major cranial nerves with subsequent 
advancement to involve the skull base and brain. The treatment for these advanced cases 
often involves major surgical resection and the long term outcomes are poor. 
 
The neurotropic factors that allow certain malignancies to spread along nerves are 
unknown. Previous work has identified increased expression of certain neural cell 
adhesion molecules thought to be involved in facilitating perineural spread. 
Lymphocytic infiltration is often observed adjacent to areas of perineural invasion and 
the role of this remains unclear. 
 
The objective of this study is to increase our understanding of neurotropism by 
identifying the genetic factors that allow the perineural spread of malignancies. We will 
analyse the features of any lymphocytic infiltration with flow cytometry of tumour tissue 
and blood samples. We also aim to: (i) establish perineural carcinoma cell lines using 
human tumour cells; (ii) develop a mouse model of perineural carcinoma spread using 
human tumour tissue and human nerve tissue, and  
(iii) analyse perineural samples using proteomics. After the necessary ethical approval 
and patient consent has been obtained, the cell line and mouse model will be useful for 
future molecular studies to assist in drug development, and the testing of these 
treatments can be undertaken in a mouse model. 
 
The epidemiology of this disease remains uncertain. We aim to collect patient clinical 
history (prospectively and retrospectively) in regards to this disease and create a 
database of patients with large nerve perineural spread for epidemiological studies. 
This will help us track patients, and identify trends and risk factors for this disease, as 
well as contribute to our understanding of the natural history of this problem. 
 
This project would contribute to the understanding of the mechanism of neurotropism, 
and help with the identification of high risk groups for perineural spread and the 
development of therapies. This may have relevance regarding the perineural spread of 
other tumour types also. 
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5. Methods 
 
(a) Patients  
Patients identified with large nerve perineural spread of head and neck malignancy will 
be invited to participate in the study. Approximately 20 new patients with perineural 
spread are seen at the Head and Neck Clinic at the Princess Alexandra Hospital each 
year. Patients with large nerve perineural disease present with clinical or radiological 
evidence of perineural spread. The current treatment for perineural spread of head and 
neck malignancy is often surgical resection and post operative radiation therapy 
 
Patient clinical history will be collected through retrospective review of patient clinical 
charts and/or prospective data collection at the outpatient clinic via interview or by 
contacting patients at home via the telephone. This information will be stored on a custom-
designed large nerve perineural database. All information will be kept confidential with 
restricted access to the investigators only. 
 
Patients due for excision of head and neck malignancy without evidence of perineural 
invasion or with small nerve (incidentally noted and focal) perineural invasion will also be 
used to allow for comparative control analysis. These patients will be de-identified prior 
to analysis. Normal peripheral nerve tissue from patients undergoing routine 
parotidectomy will also be utilised after de-identification for comparative control analysis. 
Fresh samples of perineural carcinoma tumour will also be harvested at the time of a 
patient’s surgery for three purposes: (i) to analyse immune filtrate by flow cytometry; (ii) 
to establish a perineural carcinoma tumour cell line via two methods (details below); and 
(iii) to develop a mouse model of perineural carcinoma with the use of fresh human 
tumour tissue (details below). Along with fresh tumour tissue, consenting patients with 
perineural carcinoma will have a small volume of blood taken (maximum 20mL) for 
analysis of immune cell subsets after de-identification. 
 
Consenting patients will have snap frozen biopsy specimens and paraffin sections 
taken at the time of their surgery. Paraffin sections for previous skin cancer excisions 
will also be analysed from those patients with perineural spread, if available. Fresh 
tissue samples will be stored in appropriate tissue media. 
 
The study is ongoing, with the intention of analysing specimens and tracking participants 
with large and small nerve perineural spread of head and neck malignancy and head and 
neck malignancy without perineural spread on a perineural database.. 
 
(b) Specimen Analysis 
 
The presence of malignancy, perineural spread and surgical margins will be confirmed 
using standard histopathological methods (Sullivan & Nicolaides Pathology, Envoi 
Pathology, Pathology Queensland). Snap frozen biopsies will be analysed using 
microarray gene chip techniques to identify the upregulation and downregulation of 
various genes. Paraffin sections will be stained for further immunohistochemical analysis. 
Targets for immunohistochemical analysis will be determined from the results of the 
microarray analysis. Fresh tumour and blood will be stored in appropriate tissue media 
until further use in lymphocyte analysis, cell cultures and mouse model (see below). 
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(b)(i) Details of Genetic Analysis 
 
RNA extraction from tissues  
Five 5-micron sections will be cut from the paraffin tissue blocks and placed on superfrost 
slides (Q.I.M.R. Histotechnology Unit). One slide will be stained with Haematoxylin and 
Eosin (H+E) for reference. H+E stains will be applied to the 5 remaining unstained slides 
allowing malignant tissue to be isolated and microdissected from other cells present in the 
lesion. Perineural involvement will be harvested under microscopic guidance and RNA will 
be purified and extracted using the Qiagen RNeasy FFPE Kit. Real time PCR will then be 
performed to amplify DNA within the samples and assess the quality and integrity of the 
RNA product. 
 
Microarray analysis  
Microarray analysis will be undertaken to assess any differences in genetic expression 
between the study groups. The DASL™ assay (cDNA-mediated annealing, selection, 
extension, and ligation) and Illumina BeadArray™ (Illumina, San Diego, United States of 
Amercia) will be used. Whole genome expression profiling from formalin-fixed and 
paraffin-embedded (FFPE) tissues can be achieved with this technology. 
 
The Whole-Genome DASL Assay will convert total RNA to cDNA using biotinylated 
oligo(dT) and random nonamer primers. The biotinylated cDNA is then annealed to the 
DASL Assay Pool (DAP) probe groups. Probe groups contain oligonucleotides specifically 
designed to interrogate each target sequence in the transcripts. The assay probe sets 
consist of an upstream oligo containing a gene specific sequence and a universal PCR 
primer sequence (P1) at the 5' end, and a downstream oligo containing a gene-specific 
sequence and a universal PCR primer sequence (P2') at the 3' end. The upstream oligo 
hybridizes to the targeted cDNA site, and then extends and ligates to its corresponding 
downstream oligonucleotide to create a PCR template that can be amplified with universal 
PCR primers (P1 and P2). The resulting PCR products are hybridized to the HumanRef-8 
Expression BeadChip to determine the presence or absence of specific genes. This high-
value content provides genome-wide transcriptional coverage of well-characterized 
genes, gene candidates, and splice variants, with a significant portion targeting well-
established sequences supported by peer-reviewed literature. The array is then scanned 
for intensity data using the BeadArray Reader scanner (Illumina, San Diego, United 
States of America). The data will then be analysed for evidence of variation in up-
regulation or down-regulation of genes between the three study groups. Based on the 
findings of microarray analysis, targeted immuno-histochemistry will then be undertaken 
for validation and analysis of ideal target proteins. 
 
(b)(ii) Details of perineural carcinoma lymphocyte analysis 
 
Fresh tumour tissue is separated by forceps into small pieces and pushed through a cell 
strainer to form a single cell suspension (in some instances hyaluronidase/collagenase will 
be used to assist with tumour digestion). The single cell preparation is stained with 
antibodies against immune cell surface markers (e.g. CD4, CD8) and analysed via flow 
cytometry. The blood samples will be processed in the laboratory after de-identification 
with Ficoll-Paque to yield a mononuclear cell preparation. This single cell preparation will 
be stained with the same antibodies used for the tumour tissue and analysed on the flow 
cytometer. Cell populations in the blood and tumour tissue will be compared to determine if 
particular immune cells are enriched in the tumour. 
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(b)(iii) Details of perineural cell line 
 
Fresh samples of perineural carcinoma tumour tissue will be harvested at the time of 
surgery and placed in tissue media. This tumour will be processed and stored in 
appropriate conditions and media to permit the growth of pure perineural tumour cells in 
an attempt to establish an immortal cell line. Cell cultures will be monitored weekly for 
cell growth by light microscopy and immortalised cells will be frozen in liquid nitrogen. 
 
In an alternative method for producing an immortal cell line, perineural SCC tumour cells 
will be cultured in vitro with the ROCK kinase inhibitor, Y-27632 (Sigma). This ROCK 
kinase inhibitor has been successfully used in the literature to immortalise primary human 
keratinocytes (J. Clin. Invest. (2010) 120: 2619-2626). Cell cultures will be monitored 
weekly for cell growth by light microscopy and immortalised cells will be frozen in liquid 
nitrogen. 
 
(b)(iv) Details of mouse model of perineural carcinoma 
 
Ethics approval for the use of a mouse model for epithelial cancers will be obtained 
through both the QIMR and UQDI Animal Ethics Committee. This work will be undertaken 
in the secure QIMR/TRI Animal Research facility. Fresh samples of perineural tumour 
tissue will be harvested at the time of surgery and placed in tissue media. This tissue will 
be processed and stored at QIMR and TRI. Normal human nerve tissue harvested at the 
time of routine parotid surgery will be transplanted into immunocompromised (nude) mice. 
Tumour tissue will then be injected into the subcutaneous tissue surrounding the nerve 
and into the flank of the mice. Mice will be observed and assessed and tumour transferred 
to other mice to immortalise this model. The animal will be sacrificed once tumour growth 
is deemed excessive or when the animal is no longer viable. Following euthanasia, the 
tissue will be assessed for nerve invasion. This model will allow the testing of novel 
treatments for perineural SCC as they are developed. 
 
(b)(v) Details of Proteomic Analysis 
 
Fresh / Paraffin embedded / Snap frozen samples of perineural carcinoma tumour tissue 
will be sent to the Children’s Medical Research Institute Biomedical Proteomics facility for 
analysis to determine the kinase and proteome pathways in perineural spread that may 
suggest therapeutic strategies. Using Kinomics (study of a tissue’s near entire 
complement of protein kinases (PKs) at any one time) assess altered protein kinases. In 
addition, utilizing proteomics to identify altered protein expression profiles by SWATH-MS 
(reliable and quantitative new MS-based technology to obtain data on a proteome-wide 
scale). The data from SWATH-MS after analysis will be returned to clinicians to correlate 
with patient outcomes. Data arising will be de-identified before provision to researchers. 
 
 
6. Clinical trials 
involved Nil. 
 
7. Procedures Involving the Subject 
 
(a) Invasive procedures  
Biopsy samples will be taken at the time of the patient’s surgery. The samples will be 
taken from tissue due to be excised during the surgery, independent of the study. Normal 
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nerve tissue from parotidectomy samples will be taken from tissue due to be excised 
during the surgery, independent of the study. 
 
Blood collection from consenting patients by qualified and trained personnel of 
Queensland Health will take place during the patients operation whilst the patient is 
anaesthetised. The blood will be collected from intravenous lines which are inserted for 
the purpose of the operation. 
 
(b) Procedures involving x-rays or ionising radiation – Nil 
 
(c) Facilities for dealing with contingencies  
The normal hospital protocols will be followed in dealing with contingencies, although 
none are expected. 
 
8. Assessment of Participants 
See attached Patient Information Sheet and Consent Form 
 
9. Sources of Funding 
 
2011 - Princess Alexandra Hospital Research Foundation Research Grant  
2012 - Dr Timothy Warren was funded by the Princess Alexandra Hospital Research 
Foundation through a Clinical Research Fellowship. 
2014 – PA Research Support Scheme Small Grant.  
2016 – PA Research Support Scheme Project Grant 
 
10. Sources of Drug Supply  
Nil. 
 
11. Formulation of Placebo 
Nil. 
 
12. Hospital Resources Required  
Pathology and radiology services will be used as determined necessary by the treating 
clinician, independent of the study. In addition, all Pathology services will be asked to 
provide fresh tumour and/or formalin-fixed paraffin-embedded tissue blocks. 
 
(a) Notification of other Hospital Units/Departments that may be involved 
Arrangements have been made with Pathology Queensland, Envoi Pathology and 
Sullivan Nicollaides Pathology to provide tissue blocks when available and as 
required. 
 
(b) Use of Hospital Facilities  
All samples are being analysed in the accredited research facilities of QIMR and the 
Diamantina Research Institute. Some patient samples will be sent to ProCan. 
 
 
The ProCan project is a major new initiative that is being established at the Children’s 
Medical Research Institute (CMRI) at Westmead. The goal of ProCan is to use a novel 
approach for analyzing the protein content of small tissue samples to complete a 
comprehensive analysis of all cancers that occur in adults and also in children. This has 
potential to support development of improved approaches to cancer diagnosis, and to 
enable more precise recommendations for the effective treatment of cancer patients. 
123 
 
 
ProCan at CMRI consists of a large scale laboratory facility and research expertise. The 
project will be conducted in collaboration with research groups external to CMRI, who hold 
existing sets of human cancer tissue samples and / or cancer cell lines and information. 
These sample / data sets have been collected from people who have had cancer in the 
past. ProCan will not collect samples or data from patients directly. 
 
The essential elements of ProCan are i) a purpose built facility and ii) a dedicated CMRI 
research team. 
 
The ProCan facility comprises a core of mass spectrometer instruments housed in tightly-
controlled environmental conditions. Other rooms house sample barcoders and storage 
freezers, 
 
Pressure Cycling Technology (PCT) machines, and liquid handling robotics. This is one of 
only two "industrial-scale" proteomics facilities internationally, and the only one analysing 
cancer samples. 
 
Standardised equipment and Standard Operating Procedures that will be applied across 
all ProCan research, is a key feature of the project that will accelerate discovery and 
enable ProCan to achieve its goal and purpose. 
 
 
 
13. Participant Information  
See attached Patient Information Sheet and Consent Form 
 
14. Consent Form  
See attached Patient Information Sheet and Consent Form 
 
15. Ethical Considerations 
 
(a) Benefit Anticipated from the Study  
This research aims to improve our understanding of the perineural spread of head and 
neck malignancies and identify neurotropic factors that may be associated. The outcomes 
will provide information to help develop tests to identify those patients with head and neck 
malignancies at risk of perineural spread. The establishment of a perineural carcinoma 
cell line and animal model will greatly improve our ability to understand the mechanism of 
perineural spread and assist in the development of potential drug treatments. 
 
(b) Risks  
Nil. The study only involves analysis of samples collected at the time of surgery which 
were due to be excised during that surgery. The surgery performed is dependent upon 
the treating clinician and independent of the study. 
 
(c) Research on People in Dependent Relationships 
Nil. 
 
(d) Normal Volunteers  
Biopsy samples of normal great auricular nerve will be taken at the time of parotid 
surgery. The samples will be taken from tissue due to be excised during the surgery, 
independent of the study. 
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(e) Protection of Privacy and Preservation of Confidence  
All tumour samples will be de-identified, coded and patient information only available to 
the investigators. Tumour samples may be used in further studies after the necessary 
ethical approval and patient consent has been gained. Any information obtained in 
connection with this study project will remain confidential. This information will be stored 
for future research on risk factors for this disease and how this disease can best be 
prevented and managed. 
 
(f) Restriction of the Use of the Data  
The material will be used in a de-identified state with the patient information only 
available to the investigators. 
 
(g) Any Other Particular Ethical Consideration  
Animal research will only be conducted with the approval of the QIMR Animal 
Research Ethics Committee. 
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10.2 Perineural consent 
 
Participant Information Sheet 
 
and Consent Form 
 
 
 
Studying the Factors Involved in the Perineural Spread of 
Head and Neck Malignancy 
 
 
 
 
Part I - What does my participation in the study involve? 
 
1. Introduction 
 
You are invited to participate in this study because you have been identified as a patient with a 
cancer of the head and neck. The head and neck cancer may or may not have demonstrated 
invasion into a nerve otherwise known as perineural spread. This Participant Information Sheet 
and Consent Form tells you about the study. It explains what is involved to help you decide if you 
want to take part in the study. Please read this information carefully. Ask questions about anything 
that you do not understand or want to know more about. Before deciding whether or not to take 
part you might want to talk about it with a relative, friend or Doctor. 
 
2. What is genetic research? 
 
 
Genes are what make up DNA – the chemical structure carrying your genetic information that 
determines many human characteristics such as the colour of your eyes or hair. Researchers 
study genes in order to understand why some people have a certain disease such as perineural 
spread of head and neck cancer and why some people do not. 
 
3. What is the purpose of this research? 
 
Cancers of the head and neck are named after the type of cell from which they originate, for 
example basal cell carcinoma, squamous cell carcinoma and melanoma. These cancers are very 
common, particularly in Queensland. When these cancers demonstrate perineural spread (i.e 
invades into and spreads along nerves) they can be difficult to treat. The mechanism of perineural 
spread remains unknown, and the genetic factors involved have never been assessed. Our aim is 
to investigate the mechanism of perineural spread through gene analysis and cell studies of 
tumour samples. We will compare head and neck cancers with perineural spread to head and 
neck cancers which do not have perineural spread. We are also preparing a database of cases of 
perineural spread and we would like to collect clinical information to help doctors determine how 
and why this disease occurs. It is hoped that the information gained will lead to improved treatment 
and detection of head and neck cancers with perineural spread in the future. 
 
4. Do I have to take part in the research? 
 
Participation in research is voluntary. It is up to you to decide whether or not to take part in this  
study. If you do decide to take part you will be given this Participant Information Sheet and a 
Consent Form to sign and you will be given a copy to keep. If you decide to take part you can 
change your mind later and withdraw from the study at any stage, for any reason. 
 
5. What will happen to me if I take part? 
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Your participation in this study will only proceed after a signed consent form is received. The 
research is being conducted by the Queensland Institute of Medical Research (QIMR), Diamantina 
Research Institute, Children’s Medical Research Institute (Westmead, NSW) and the Princess 
Alexandra Hospital. The study involves the analysis of samples taken at the time of your surgery. 
Your participation will not alter the type or length of surgery you are due to have. Only tissue that 
was due to be excised will be analysed, independent of your participation in the study. No 
additional visits to hospital will be required because of the study. This study does not involve any 
alteration to your usual medical treatment. 
 
Analysis of your specimens involves microscopic examination using special marking stains, 
powerful computer technology and growth factors to identify genes or cells thought to be involved 
in cancer spread. A purified collection of tumour cells or cell line may be generated from your 
cancer tumour, which may be kept alive in the laboratory for long periods. This will involve the use 
of these tumour cells in a model of perineural spread of head and neck cancers, and may 
eventually allow the testing of treatments for this disease as they are developed. Your tissue 
samples, or a portion thereof, may be assessed for the proteins it contains. Cancer cells change 
the proteins that they make and we would like to work out what these changes are in head and 
neck cancer. A sample of your blood (20mL maximum) will be collected when you are under a 
general anaesthetic for your operation, and will be used to compare the blood cell profile of your 
blood and the tumour. The specimens are analysed in a de-identified state so the results cannot 
be directly linked back to you as an individual. De-identified results from testing samples may be 
sent to clinicians to be re-identified and compared with clinical diagnosis and prognosis. Only 
clinicians will access your personal data. Outcomes supplied to researchers would again be de-
identified. 
 
 
We will ask you to answer questions on your medical history to help us to gather information on 
why this disease occurs. This information will be collected by doctors and researchers from the 
Princess Alexandra Hospital. Any information obtained in connection with this study project that 
can identify you will remain confidential. This information will be stored for future research on risk 
factors for this disease and how we can best prevent and manage this disease. We will collect 
information at your visits to the hospital or over the phone from home if this is acceptable. If you do 
not wish to answer a question you may skip it and go to the next question, or you may stop 
immediately. Information about you may be obtained from your health records held at this and 
other health services for the purpose of this research. By signing the consent form you agree to 
the study team accessing health records if they are relevant to your participation in this study. 
 
6. What will happen to my samples? 
 
Your head and neck cancer specimen is required for this project, and only a sample of the tissue 
that was due to be excised by your treating doctor will be collected for research purposes. We 
would like your extended consent to store your cancer tumour specimen for future use in research 
studies that are an extension of this study. Alternatively we may use your sample for future 
research that is closely related to the original study. Further information can be found in the 
section of banking. A de-identified portion of your tissue sample may be sent to research partners 
for further scientific analysis. 
7. What is the potential impact to my family if I take part? 
 
There will be no impact to your family through your participation in this study. We hope to assist 
the future treatment and detection of head and neck cancer with perineural spread, which may be 
of benefit to your family. 
 
8. Will I be given the results of the study? 
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Your treating Doctor will discuss the results of the standard pathologic analysis with you. The 
results of the testing into the causative factors for perineural spread will be used to identify trends 
and methods of early detection and will not be available on an individual basis. Results of testing 
by researchers / academics will be published in a completely de-identified format and can be 
provided to you on request. 
 
9. What risks or problems can I expect from the study? 
 
There are no foreseeable risks or problems from your participation in this study. We are assessing 
the genetic and cell factors of the head and neck cancer that was surgically removed from you. 
This study is designed to assist future treatment and detection of head and neck cancer with 
perineural spread. 
 
 
 
 
10. Will I benefit from this study? 
 
You will not derive any direct benefit from your participation in the study. The results of this study 
will not provide you with any direct benefit because the link between you and your head and neck 
cancer will be removed before your cancer tumour is analysed. However, it may provide valuable 
information to improve the management of people with perineural spread of head and neck cancer 
in the future. 
 
11. Will drug or biotechnology companies be able to use my sample for profit in the future? 
 
There is the possibility that this research may result in commercially viable technology or 
treatments. However, you will not be able to claim financial benefit from any discoveries arising 
from the use of your cancer sample. 
 
12. What is banking and what is a bank? 
 
“Banking” is storing health information and/or blood or tissue for future research studies. A “bank” 
is the place where the health information and/or blood or tissue is stored. 
 
13. Why do you want to store my tissue? 
 
The Principal Investigator wants your permission to store your head and neck cancer sample for 
future research. The Principal Investigator would like you to take part in this bank because you are 
booked for an operation to have a cancer removed from the head and neck region. In the future, 
other doctors and scientists at this and other medical and research centres may use your cancer 
sample to learn about many different diseases and conditions. Their goal is to improve health 
outcomes and develop new treatments. 
 
14. How will the samples for the bank be obtained? 
 
The Principal Investigator will store your leftover head and neck cancer specimen after your 
planned operation in a bank. This procedure was recommended by your doctor as part of your 
routine care for your condition and is not part of the research. 
 
Your participation in this study is entirely voluntary. You may withdraw from the study at any stage 
without influencing your ongoing treatment.  
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15. What will happen to information about me? 
 
By signing the consent form you consent to the study doctor and relevant research staff collecting 
and using personal information about you for the study project. Any information obtained in 
connection with this study project that can identify you will remain confidential. Your personal 
details will be stored at the Princess Alexandra Hospital. This information will only be available to 
your doctors and the principal investigators of the study. Information about your participation in this 
study may be recorded in your health records. Your information will only be used for the purpose 
of this study project and it will only be disclosed with your permission, except as required by law. 
 
16. How will my confidentiality be protected? 
 
Your sample will have all identifiers removed (ie name and personal details) and be replaced with 
a code. It will be possible to re-identify you using the code. The information containing identifiers 
will be kept at the Princess Alexandra Hospital or with treating doctor, who will have access to 
these details. Your samples and data will not be released for any use without your prior consent 
unless required by law. 
 
17. Will the study results be published? 
 
It is anticipated that the results of this study will be published and or presented in a variety of 
forums. In any publication and/or presentation, information will be provided in such a way that you 
cannot be identified, except with your express permission. 
 
18. What if something goes wrong? 
 
If you suffer any distress or psychological injury as a result of this study, you should contact the 
study team as soon as possible, who will assist you in arranging appropriate treatment and 
support. 
 
19. Who is organising and funding the research? 
 
This study is being conducted by Professor Ben Panizza through the Princess Alexandra Hospital. 
Funding for the research has been provided by the Princess Alexandra Hospital Research 
Foundation. 
 
20. Who has reviewed the study? 
 
All research in Australia involving humans is reviewed by an independent group of people, called a 
Human Research Ethics Committee (HREC). This study has been reviewed and given approval by 
the Metro South Human Research Ethics Committee. 
 
21. Further information and who to contact? 
 
If you would like any further information on this study you may contact Professor Ben Panizza on 
(07) 3176 5266. 
 
If you would like to talk to someone not directly involved with the study for any further information 
regarding your rights as a study patient or should you wish to make a complaint to people 
independent of the study team, you may contact the Metro South Human Research Ethics 
Committee. (Tel: (07) 3443 8049) 
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 Question  Who to contact  Phone / Facsimile 
 General questions 
or 
 
Study Coordinator 
 Ph: (07) 3176 3219 
   
Fax: (07) 3176 5213  
concerns during the 
        
    
Ph: (07) 3176 5266  
study 
 
Principal Investigator 
 
   
Fax: (07) 3176 5213            
   
Professor Ben 
Panizza 
 Ph: (07) 3176 5266 
 
Questions about the 
  
Fax: (07) 3176 5213 
   
    
 
way the research is 
        
    
Ph: (07) 3443 8049  
being conducted 
 
HREC Coordinator 
 
   EthicsResearch.PAH@health.qld.
gov.au      
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Withdrawal of Participation Form 
 
Title 
 
HREC No 
 
Location 
 
Principal 
Investigator 
 
Studying the Perineural Spread of Head and Neck Malignancy 
 
HREC 2003/197 
 
The Princess Alexandra Hospital 
 
Professor Ben Panizza 
 
 
 
I hereby wish to WITHDRAW my intent to participate further in the above research project and 
understand that such withdrawal will not jeopardise my future health care. 
 
 
I request that my entire cancer specimen collected and banked be removed and destroyed if it 
is still identifiable.  
Participant Name (Printed) 
 
 
Signature  
 
 
Date  
 
 
In the event the participant decided to withdraw verbally, please give a description of the 
circumstances.  
Coordinating Investigator to provide further information here:  
 
 
 
 
 
 
 
 
 
 
Coordinating Investigator to sign the Withdrawal of Consent Form on behalf of a participant if 
verbal withdrawal has been given: 
 
 
Participant Name (Printed) ___________________________________________________ 
 
 
Signature 
 
 
___________________________________________________ 
 
 
Date 
 
 
_________________________________________    
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Consent Form 
 
 
Study Title Studying the perineural spread of Head and Neck Malignancy  
HREC No HREC 2003/197 
Location The Princess Alexandra Hospital 
 
13. I have read the attached Participant Information Sheet outlining the nature and purpose 
of the research study and I understand what I am being asked to do. 
 
14. The purpose, procedures, risks and possible benefits have been explained to me. I have 
had the opportunity to ask questions and I am satisfied with the answers I have received. 
 
15. I understand that I can withdraw my consent to participate in this study by completing a 
“Withdrawal of Consent” form. I can also specify whether I wish to have my head and neck 
cancer sample already collected and stored deleted/or destroyed, if it is still identified as 
mine. 
 
16. I understand that if I decide to discontinue the study treatment, I may be asked to attend 
follow-up visits to allow collection of information regarding my health status. Alternatively, 
the investigator/sponsor will request my permission to access my medical records for 
collection of follow-up information for research and analysis. 
 
 
 
I hereby voluntarily consent to: 
 
(c) Medical practitioners, other health professionals, hospitals or laboratories outside 
this institution releasing information concerning my condition and treatment Yes  No  
which is needed for this study and understand that such information will remain 
confidential. 
 
 
(e) The use of my DNA and/or tissue for the purpose of this research 
study only 
 
(f) The use of my DNA and/or tissue for the purpose of this research 
study and any closely related future research studies 
 
(g) The use of my clinical information for the purpose of this research  
 
  
Yes  No  
Yes  No  
Yes  No         
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        Name of Participant                    Signature of Participant Date  
 
 
 
 
 
 
 
Name of Member of Study Team      Signature of Member of Study Date 
Team  
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10.3 Animal ethics approval NSG-A2 
 
Mice - genetically modified (NSG-A2 (HLA-A2) , Mix, Adults, ) 
12 2017 Dec  Initial approval 31 31 
Description Amount Balance 
Approval Details 
Office of Research Ethics 
Director 
Nicole Shively 
Animal Ethics Approval Certificate 11- Dec -2017 
Please check all details below and inform the Animal Ethics Unit within 10 working days if anything is incorrect. 
Activity Details 
Chief Investigator: Dr Fiona Simpson, Chemistry and Molecular Biosciences 
Title: Novel Therapeutic Strategies for Treatment of Cutaneous SCCHN with Perineural Invasion 
AEC Approval Number: UQDI/456/17 
Previous AEC Number: 
Approval Duration: 12- Dec-2017 to 12-Dec -2020 
Funding Body: 
Group: Health Sciences 
Other Staff/Students: Glen Boyle, Richard Brown, Natasha Broit, The University of Queensland Diamantina  
Institute (UQDI), Priscila Oliveira De Lima, Karen Knox, Rodrick Rupan, Brian Tse,  
Christa Singh, Michelle Spraggon, Kamil Sokolowski, Alistair Zealey, Lauren Windt, Tina  
Weaver, Thomas Rosenfeld, Ai Preston, Ben Panizza, Brad Buchan, Michael Piper, Cora  
Lau, Rona Barugahare 
Summary 
Subspecies Strain Class Gender Source Approved Remaining 
Mice - genetically  
modified 
NSG-A2 (HLA- 
A2)  
Adults Mix 31 31 
Permits 
Provisos 
Location(s): PA Hospital Translational Research Institute (TRI) 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
Page 1 of 2 
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration 
1 . When ordering animals from Animal Breeding Houses 
2 . For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and  
contact phone number. 
3 . When you need to communicate with this office about the project. 
It is a condition of this approval that all project animal details be made available to Animal House OIC. 
( UAEC Ruling  14/12/2001) 
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied  
for this project. 
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 11-Dec-2017) 
Please use this Approval Number: 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
Page 2 of 2 
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10.4 Animal ethics approval C57BJ/6 
 
Mice - non genetically modified (C57BJ/6, Mix, Adults, ) 
2017  Sep  13 Initial approval 72 72 
Description Amount Balance 
Approval Details 
Office of Research Ethics 
Director 
Nicole Shively 
Animal Ethics Approval Certificate 12- Sep -2017 
Please check all details below and inform the Animal Ethics Unit within 10 working days if anything is incorrect. 
Activity Details 
Chief Investigator: Dr Fiona Simpson, Chemistry and Molecular Biosciences 
Title: Towards Effective Treatment of Cutaneous SCC of the Head and Neck with Perineural  
Invasion 
AEC Approval Number: UQDI/359/17 
Previous AEC Number: 
Approval Duration: 13- Sep-2017 to 13-Sep -2020 
Funding Body: 
Group: Health Sciences 
Other Staff/Students: Michael Piper, Christa Singh, Rodrick Rupan, Karen Knox, Richard Brown, Priscila   
Oliveira de Lima, Natasha Broit, Cora Lau, Michelle Spraggon, Brad Buchan, Kylie  
Hengst, Peter Parsons, Glen Boyle, Kamil Sokolowski, Lauren Windt, Brian Tse, Alistair  
Zealey, Tina Weaver, Ai Preston, Rona Barugahare 
Summary 
Subspecies Strain Class Gender Source Approved Remaining 
Mice - non  
genetically  
modified 
C57BJ/6 Adults Mix 72 72 
Permits 
Provisos 
Glen Boyle, Ai Preston and Peter Parsons are listed as participants on this project. According to our records, we have not  
received a response regarding these nominations. These participants cannot work on an approved project until they have  
confirmed involvement via electronic signature or, via email notification being sent to the Animal Ethics Unit  
Administration Officer at awu.aec.hs@research.uq.edu.au  
Location(s): PA Hospital Translational Research Institute (TRI) 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
Page 1 of 2 
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration 
1 . When ordering animals from Animal Breeding Houses 
2 . For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and  
contact phone number. 
3 . When you need to communicate with this office about the project. 
It is a condition of this approval that all project animal details be made available to Animal House OIC. 
( UAEC Ruling  14/12/2001) 
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied  
for this project. 
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 12-Sep-2017) 
Please use this Approval Number: 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
Page 2 of 2 
